roche annual report finance report innovate healthcareinnovation span entire healthcare spectrum pharmaceutical diagnostic company roche bring pioneer product service market stage healthcare process identify disease susceptibility testing disease atrisk population prevention diagnosis therapy treatment monitor focus product deliver significant benefit patient health professional core element business strategy key reason success researchintensive company longterm strategic focus roche strive deliver sustainable value stakeholderstable content finance report roche group finance brief finance brief financial review operating result nonoperate result cash flow net cash balance sheet pension post employment benefit roche security financial risk international financial reporting standard roche group consolidated financial statement income statement balance sheet cash flow statement statement recognise income expense statement change equity note roche group consolidated financial statement report group auditor multiyear overview supplementary net income ep information roche security roche holding ltd basel financial statement income statement balance sheet note financial statement appropriation available earning report statutory auditor finance report finance brief key result operate profit margin exceptional item local sale growth sale pharmaceutical diagnostic group change sales mchf mchf chf sales ebitda operating profit exceptional item profit continue business exceptional item net income net cash equity equity ratio core epsin chf dividend sharein chf ebitda earning exceptional item financial income financing cost tax depreciation amortisation include impairment correspond operate profit exceptional item depreciation amortisation include impairment definition core ep propose board director local currency finance executive team erich hunziker chief financial officer hubert buck management development peter eisenre taxis insurance marco frei pension asset management andreas knierzinger treasury steve krognes corporate development karl mahler investor relation erwin schneider accounting control finance report finance brief sale group sale grow local currency billion swiss franc drive primarily fast organic growth pharmaceutical division pharmaceutical sale increase local currency billion swiss franc strongly outperform global market thank key oncology product tamiflu bonvivaboniva lucentis pharmaceutical sale account group sale oncology product sale grow local currency billion swiss franc represent pharmaceutical sale diagnostic sale increase local currency billion swiss franc drive primarily centralize diagnostic business operating result operate profit exceptional item increase local currency billion swiss franc base strong business growth continue productivity improvement record profitability operating profit margin exceptional item percentage point expenditure increase local currency billion swiss franc represent group sale significant investment new biotechnology manufacture facility treasury increase net financial income million swiss franc compare million swiss franc partial redemption lyon convertible note repayment bank debt reduce debt billion swiss franc financial condition increase net cash billion swiss franc billion swiss franc increase equity ratio decrease debtequity ratio rating moodys rating standard poor maintain net income increase overall net income billion swiss franc primarily strong operating performance shareholder return market capitalisation increase billion swiss franc share price price nonvoting equity security increase core ep swiss franc outpace swiss franc sale growth percentage point increase propose dividend swiss franc represent consecutive year dividend growth finance report roche group financial review operating result group operating result sale operating profit exceptional item billion chf growth billion chf sale continue business annual result strong operating performance term topline sale growth profit margin mainly drive pharmaceutical division total sale grow local currency swiss franc dollar billion swiss franc pharmaceutical division contribute group sale diagnostic division represent incremental sale increase billion swiss franc achieve organic growth primarily drive strong demand group oncology drug herceptin avastin mabtherarituxan tarceva antiinfluenza drug tamiflu bonvivaboniva lucentis sale increase absorb million swiss franc lower rocephin sale globally follow product patent expiry july group operating profit exceptional item increase local currency billion swiss franc correspond operate profit margin grow percentage point drive increase pharmaceutical percentage point offset decline margin diagnostic percentage point overall margin growth achieve time group continue increase investment strong development pipeline launch prelaunch activity exchange rate impact sale operate profit growth express swiss franc moderate swissfranc growth percentage point high localcurrency growth average exchange rate dollar high euro high japanese yen lose finance report roche group financial review group operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale operating profit exceptional item margin ebitda margin group operating result development result compare pharmaceutical diagnostic corporate group sale increase local currency operate profit exceptional item increase local currency margin percentage point increase ebitda increase local currency margin percentage point increase pharmaceutical operating result pharmaceutical division show strong sale increase growth local currency swiss franc dollar billion swiss franc outpace growth global market factor operating profit exceptional item billion swiss franc represent growth local currency consequently margin increase percentage point marketing distribution cost significantly increase local currency billion swiss franc reflect support recently launch onmarket product prelaunch activity global rollout new indication investment pipeline continue billion swiss franc expenditure anincrease local currency pharmaceutical division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item margin ebitda margin salesthe major growth driver oncology transplantation virology franchise include tamiflu key oncology franchise significantly outpace market renal anemia franchise decline slightly biennial selling price cut change reimbursement system epogin japanese market finance report roche group financial review pharmaceutical division sale therapeutic area sale change therapeutic area mchf sale local currency oncology inflammationautoimmunetransplantation virology metabolismbone renal anemia total exclude tamiflu growth profitability pharmaceutical division primarily product herceptin avastin tamiflu mabtherarituxan lucentis tarceva bonvivaboniva xeloda cellcept xolair represent portfolio grow generate billion swiss franc additional sale overall product grow rocephin real decline patent expiry decline product primarily generic erosion affect copegus roaccutane pharmaceutical division sale product change sale local mchf sale currency therapeutic area mabtherarituxan oncology iat herceptin oncology avastin oncology tamiflu virology neorecormonepogin anemia oncology cellcept iat pegasys virology xeloda oncology tarceva oncology xenical metabolismbone xolair respiratory disease kytril oncology nutropin metabolismbone bonvivaboniva metabolismbone valcytecymevene virology lucentis ophthalmology pulmozyme respiratory disease rocephin infectious disease neutrogin oncology activasetnkase cardiovascular disease total product product total inflammationautoimmunetransplantation finance report roche group financial review mabtherarituxansale growth drive high sale volume particularly europe rest world exclude japan row primarily increase usage mabtherarituxan line treatment indolent aggressive nonhodgkin lymphoma nhl high treatment rate nhl maintain price increase contribute sale growth initial sale record treatment new rheumatoid arthritis indication europerow additional driver overall growth growth potential expect maintenance indicationtreatment immediately follow firstline therapy indolent nonhodgkin lymphoma herceptin growth second high selling product continue drive increase market share herpositive adjuvant breast cancer adj launch indication additional country roche estimate end herceptin market share adj key market france germany italy spain united kingdom penetration rate set outside country considerably low growth rate appear flatten early rapid adoption adjuvant treatment contribute growth less extent price increase effective avastin sale continue grow strongly particularly europerow avastin launch market worldwide initial indication firstline metastatic colorectal cancer mcrc avastin achieve high penetration rate follow launch early continue growth primarily drive usage avastin firstline advanced nonsmall cell lung cancer nsclc approve food drug administration fda combination chemotherapy october unapprove usage metastatic breast cancer mbc growth modest increase usage firstline mcrc roche file firstline advanced nsclc europe firstline mbc file additional filing enlarge european firstline mcrc label match broad label plan half file treatment advanced renal cell carcinoma rcc europe schedule tamiflusale continue increase mainly government pandemic stockpiling contribute total sale increase retail sale relate pandemic preparedness seasonal sale lower year absence severe flu season europe japan calendar year significant pandemic order delivery neorecormonepogingrowth neorecormon drive increase usage oncology renal anemia segment offset continued pricing pressure epogin sale japan decline biennial selling price cut change reimbursement system overall sale anemia franchise slightly decline cellceptsale lead treatment mycophenolic acid mpa market particularly strong drive transplant indication increase usage treatment certain autoimmune indication currently approve continue sale growth western european country offset sale decline latin american country generic competition commence pegasys market share pegasys remain global market leader treatment hepatitis pegylate interferon sale drive increase use europerow offset decline overall decline market volume japan sale decline competition combination treatment pegasyscopegus combination approve market january xelodathe main growth driver increase usage xeloda treatment adjuvant colon cancer mcrc file gastric cancer submit europe filing include combination mcrc label include use combination avastin track half tarcevasale continue increase europerow account close overall sale month obtain approval sale drive approval second indication metastatic pancreatic cancer pricing increase europe tarceva approve treatment advance pancreatic cancer january finance report roche group financial review xolairsale growth primarily drive increase penetration asthma market less extent pricing increase outside xolair market novartis half genentech expect complete acquisition tanox partner development xolair bonvivaboniva vast majority sale come boniva capture approximately market share total prescription bonviva grant reimbursement launch european market lucentis follow approval june initial sale drive high demand exist agerelate macular degeneration amd patient previously therapie use newly diagnose patient outside lucentis market novartis rocephinsale continue decline rapidly follow patent expiry july sale significantly low marginal effect generic competition abate information product pipeline find business report sale regionsale continue grow major region north america sale grow time market drive product market genentech avastin herceptin lucentis mabtherarituxan tarceva xolair tamiflu bonvivaboniva cellcept xeloda valcytecymevene compensate million swiss franc decline sale rocephin follow patent expiry july europe group continue gain market share drive continue strong sale growth herceptin tamiflu avastin mabtherarituxan tarceva pegasys xeloda neorecormon sales japan decline biennial governmentmandate price cut effective april growth tamiflu sale japan government pandemic sale compensate low seasonal flu sale sale growth herceptin neutrogin evista mainly offset decline epogin sale decline biennial price cut new rule introduce flatrate reimbursement epoetin product dialysis patient reduce size anemia market japan pharmaceutical division sale region sale change region mchf sale local currency north america europe japan region total royalty operate incomethe increase local currency high royalty income upfront income genentech increase outlicense income roche pharmaceutical gain product divestment significant million swiss franc compare million swiss franc cost sale increase local currency significantly increase sale economy scale production product mix effect addition continue productivity improvement benefit concentrate small number production site factor compensate increase royalty expense product sale million swiss franc million swiss franc drive success mabtherarituxan tarceva xolair tamiflu gross profit share glaxosmithkline increase bonvivaboniva sale finance report roche group financial review marketing distributionthese cost increase local currency low growth sale spite continue intensive support recent product launch prelaunch activity upcoming launch significant investment boniva lucentis europe row market avastin tarceva worldwide pegasys mabtherarituxan new indication rheumatoid arthritis addition prelaunch cost avastin nsclc breast cancer mircera japan strategic marketing function strengthen sale force significantly increase reorganise specialised oncologyrenal representative additionally japan preparation early originally anticipate launch avastin tarceva launch actemra rheumatoid arthritis furthermore past month roche establish number new affiliate central eastern europe cost relate tamiflu increase properly communicate role seasonal flu pandemic planning marketing distribution cost percentage sale compare research developmentthe increase million swiss franc local currency billion swiss franc reflect high spending latestage clinical trial earlystage project drive additional indication particular oncology portfolio mabtherarituxan actemra rheumatoid arthritis research development cost percentage sale compare addition roche spend million swiss franc inlicense pipeline compound technology capitalise intangible asset require ifrs total roche spend billion swiss franc internal purchase inlicense alliance deal represent sale increase local currency general administration cost grow local currency favourable development include low restructuring cost particular chugai gain disposal property overall compensate cost project harmonise sap system europe establish share service centre european affiliate high royalty expense royalty income genentech creation new affiliate central eastern europe amortisation impairment intangible assetsthe decline local currency primarily arise genentech intangible asset fully amortise mid impairment charge million swissfranc record second half relate decision terminate development compound alliance partner pharmaceutical subdivisional result operate operate profit profit exceptional exceptional sale ebitda ebitda item item mchf mchf sale mchf sale roche pharmaceutical genentech chugai pharmaceutical division roche pharmaceutical genentech chugai pharmaceutical division finance report roche group financial review pharmaceutical division roche pharmaceutical show strong performance sale increase local currency increase operate profit local currency increase operate profit margin percentage point sale economy scale favourable product mix development low cost ratio marketing distribution research development general administration offset impact high royalty expense increase gross profit share glaxosmithkline follow high bonvivaboniva sale genentech overall cost grow significantly increase sale additionally genentech receive considerably high royalty income roche pharmaceutical sale success herceptin avastin mabtherarituxan tarceva consequence operating profit margin improve percentage point chugai report slightly low sale local currency mainly result government price cut increase tamiflu sale government pandemic planning fully offset impact price cut operate profit chugai decline million swiss franc price cut epogin reimbursement change mention previously marketing activity describe additional information pharmaceutical division subdivisional result give note consolidated financial statement andfurther information genentech chugai give note diagnostic operating result diagnostic division increase sale billion swiss franc grow local currency swiss franc dollar maintain lead market position operating profit exceptional item decrease local currency million swiss franc margin decline percentage point cash generation business remain industry average ebitda low margin primarily investment product launch continue sell price pressure combine impairment charge intangible asset sale second half additionally royalty operating income substantially low mainly expiry pcrrelate patent certain onetime income despite decline operating margin remain average division major competitor diagnostic division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item margin ebitda margin sale major driver sale growth centralize diagnostic immunodiagnostic apply science near patient testing deliver solid performance continue rollout product particular rejuvenated diabetes care portfolio combine recently launch cobas modular platform centralize diagnostic help strengthen roche position market segment lead increase growth second half finance report roche group financial review diagnostic division sale business area sale change business area mchf sale local currency diabetes care centralize diagnostic immunochemistry molecular diagnostic near patient testing apply science total diabetes care diabete care maintain number position blood glucose monitor sale billion swiss franc increase local currency follow rebound growth second half year sale accuchek blood glucose monitoring meter strip lancet increase local currency billion swiss franc insulin delivery sale grow million swiss franc global rollout new portfolio complete mid launch accuchek compact plus canada accuchek aviva japan new accuchek aviva meter experience rapid uptake market launch reverse sale decline maturation accuchek advantage line accuchek compact plus continue expand new integrate market segment command share remain meter market integrating measure test strip lancet device october food drug administration fda lift import alert bar sale accuchek insulin pump united states allow roche immediately reenter world large infusion system market centralize diagnosticssale increase local currency billion swiss franc increase roche lead highly competitive segment immunochemistry sale grow significantly market rate sixth successive year growth billion swiss franc significant immunochemistry instrument placement combine increase demand cardiac test elecsy probnp result strong reagent sale sale clinical chemistry increase volume ongoing price pressure segment mean sale decline flat market launch mid cobas analyser series labs medium workload series modular platform design integrate improve efficiency clinical chemistry immunochemistry test different sized laboratory strengthen product offer important market segment molecular diagnostic molecular diagnostic remain clear market leader sale billion swissfranc growth local currency sale virology grow local currency million swiss franc flat market support new automate platform help combat pricing pressure highly competitive segment blood screening show evidence slow growth sale million swiss franc decrease local currency increase number centre come online offset price reduction japan early year june roche begin roll europe new fully automate cobas modular blood screening system cobas taqscreen mpx multiplex test simultaneously detect hiv hcv hbv donate blood plasma roche track submit filing fda half test detect genotype low highrisk type human papillomavirus hpv near patient testing sale rise million swiss franc help improve marketing business area broad portfolio continue decentralise testing coagulation sale increase local currency million swiss franc grow trend patient selfmonitore new coagulation monitoring systems coaguchek patient selfmonitore coaguchek plus forhealthcare professional commence european rollout january october respectively launch coaguchek professional use plan quarter apply sciencein highly fragmented competitive life science market apply science grow million swiss franc twice market rate major contributor sale genome sequencer system dna sequence lightcycler system highthroughput realtime pcr andthe industrial business reagent industrial process finance report roche group financial review sale region sale continue grow ahead local market region exception northamerica north america return positive growth second half help immunochemistry rebound diabetes care sale growth japan particularly strong give acrosstheboard price cut april diagnostic division sale region sale change region mchf sale local currency north america emea japan region total europe middle east africa exclude iberia royalty operate income million swiss franc royalty operating income local currency million swiss franc lower comparative period include substantial oneoff income outlicense agreement royalty income low expiry march foundational pcr patent country outside patent expire march cost sale overall increase local currency considerably high sale growth result business area mix product mix impact high depreciation result significantly increase leasedout instrument base royalty expense million swiss franc high inlocal currency primarily centralized diagnostic cost sale percentage sale increase marketing distribution cost remain stable level increase overall investment offset significant launch expense number new diabetes care product comparative number addition sample consumption inventory writeoff low global function division business area streamline marketing distribution percentage sale decline research developmentcost decrease slightly local currency decline reflect change time project low expense thirdparty collaboration percentage sale research development cost decline general administrationthese cost increase local currency mainly increase accrual prior year royalty follow ongoing discussion contract partner addition restructuring expense million swiss franc amortisation impairment intangible assetsthe increase impairment charge million swiss franc record second half follow update division business plan technology assessment charge mainly relate intangible asset record disetronic acquisition corporate operating cost general administration cost increase million swiss franc million swiss franc explain inclusion result gain million swiss franc settlement pension plan chugai exclude corporate operating cost decline finance report roche group financial review exceptional operating item major legal casesthere income statement impact development major legal case additional information major legal case give note consolidated financial statement total operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf mchf mchf mchf mchf operating profit exceptional item major legal case operate profit operating profit increase million swiss franc local currency reflect strong business expansion continue improvement group operating performance inclusion exceptional item major legal case comparative result nonoperate result group treasury operation pension management deliver positive net financial income net income financial asset foreign exchange management exceeding financing cost million swiss franc group effective tax rate increase percentage point mainly increase effective tax rate genentech profit continue business net income increase combination positive development operate financial line absence major legal case expense compensate increase effective tax rate nonoperating result change mchf mchf chf operating profit associate company financial income financing cost profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest net financial income million chf financing cost financial income net financial income finance report roche group financial review financial income financial income show strong increase compare net income equity security million swiss franc compare million swiss franc drive strongly perform equity market disposal equity investment interest income income debt security double million swiss franc high holding increase interest rate expect return pension plan asset million swiss franc line net foreign exchange loss million swiss franc compare loss million swiss franc analysis financial income give note consolidated financial statement finance costsfinance cost million swiss franc decline compare interest expense increase result billion dollar senior note issue genentech mid partly compensate low interest expense result partial conversion lyon notes bank debt redemption debt instrument fix increase interest rate major impact financing cost interest cost define benefit plan million swiss franc slightly low analysis financing cost give note consolidated financial statement income taxesthe group effective tax rate compare rate main influence increase effective tax rate genentech interim result accounting equity compensation plan adversely affect effective tax rate genentech development genentech share price mean small accounting tax benefit record expense equity compensation plan addition tax charge genentech include certain tax credit exclude genentech chugai underlie effective tax rate slightly low rate analysis effective tax rate give note consolidated financial statement profit continue business billion chf net income billion chf profit continue businessesthe increase compare positive development operate financial line exclude exceptional item major legal case profit continue business increase billion swiss franc discontinue businessesthere significant result discontinue operation show small release provision long require comparative result include operating result remain consumer health otc business transfer bayer information discontinue business give note consolidated financial statement net income group net income increase billion swiss franc return sale margin net income attributable roche shareholder higher comparative period share net income attributable minority increase million swiss franc continually improve profit contribution genentech million swiss franc attributable genentech minority interest million swiss franc chugai minority interest dilute eps chf chf change group core increase dilute eps high net income core ep exclude exceptional item amortisation impairment intangible asset increase swiss franc swiss franc show underlying improvement group operate financial result supplementary net income ep information give include calculation profit continue business exceptional item core ep reconcile group publish ifrs result finance report roche group financial review cash flow net cash cash flow operating activity net cash income taxis billion chf billion chf condense cash flow statement mchf mchf cash generate operation increase decrease work capital cost major legal case pay operating cash flow operating activity income taxis income taxis pay activity operating activity invest activity financing activity net effect currency translation cash increase decrease cash consolidated cash flow statement give consolidated financial statement operate cash flowsthe group business operation continue strong cash generation billion swiss franc drive continued growth ebitda development business lead increase work capital mainly inventory trade receivable particular increase genentech growth business central eastern europe income tax payment increase payment genentech chugai total operating cash flow taxis increase billion swissfranc invest cash flow large investing cash flow expenditure property plant equipment billion swiss franc particularly biotechnology manufacture facility net reinvestment cash marketable security billion swiss franc comparative cash flow include receipt bayer billion swiss franc proceed divestment consumer health otc business billion swiss franc genentech purchase oceanside biologic manufacturing facility finance cash flow significant financing cash flow relate dividend payment redemption debt instrument dividend pay roche billion swiss franc billion swiss franc cash redemption debt instrument billion swiss franc purchase equity instrument cover partial conversion lyon note compare billion swiss franc sumo bond follow partial conversion lyon notes group reduce equity instrument holding realise cash inflow billion swiss franc genentech issue billion dollar senior note result cash inflow equivalent billion swiss franc genentech receive billion swiss franc stock option exercise billion swiss franc repurchase share billion swiss franc billion swiss franc finance report roche group financial review net cash december december mchf mchf change cash cash equivalent marketable security longterm debt shortterm debt net cash net cash increase billion swiss franc main driver strong cash inflow operating activity billion swiss franc expenditure property plant equipment roche dividend payment increase shortterm debt reclassification lyon note dollar european medium term note longterm shortterm debt balance sheet balance sheet billion chf liability asset net asset equity condense balance sheet december december mchf mchf change property plant equipment goodwill intangible asset noncurrent asset cash marketable security current asset total asset debt current noncurrent noncurrent liability current liability total liability total net asset capital reserve attributable roche shareholder equity attributable minority interest total equity consolidated balance sheet give consolidated financial statement noncurrent asset decrease dollar swiss franc december december decrease longterm asset swiss franc term group production facility intangible asset denominate dollar offset capital expenditure billion swiss franc finance report roche group financial review current assetsinventorie account receivable high local currency follow growth business total balance cash marketable security increase billion swiss franc result group strong cash generation debt partial conversion lyon notes repayment bank loan reduce debt billion swiss franc remain billion swiss franc carry value lyon note classify shortterm debt group option redeem note july onwards additionally movement dollar exchange rate decrease swiss franc carry value group dollardenominate debt instrument noncurrent current liabilitiesthere significant movement overall balance local currency movement currency translation transfer current non current liability total net assetsequity significant movement net income billion swiss franc roche dividend payment billion swiss franc currency translation loss billion swiss franc currency translation loss mainly arise decrease dollar relative swiss franc particularly affect balance sheet value asset liability concentration property plant equipment goodwill intangible asset debt strong financial condition group remain solidly finance equity include minority interest represent total asset total asset finance longterm pension postemployment benefit postemployment benefit plan classify define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc increase arise mainly genentech plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise fund asset management group define benefit plan oversee corporate level plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource funding status define benefit pension postemployment benefit plan mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation funding status overall group define benefit plan continue adequately fund main movement arise well expect return plan asset currency translation effect plan denominate dollar euro funding status increase increase discount rate valuation eurozone plan reduce define benefit obligation slightly finance report roche group financial review expense record income statement pension expense relate group define benefit plan million swiss franc double expense million swiss franc mainly onetime settlement gain million swiss franc arise chugai return employee pension fund japanese government exclude pension cost increase mainly change discount rate adopt end revise actuarial assumption include actuarial valuation end expect lead increase partly arise increase life expectancy detail group pension postemployment benefit give note consolidated financial statement roche security price development roche security outperform peer group healthcare companiesbut rise slightly swiss market share price market capitalisation december change share price chf nonvoting equity security genussscheinprice chf market capitalisation chf billion roche rank number peer list term total shareholder return tsr share price growth plus dividend measure swiss franc yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return roche peer group actual exchange rate total shareholder return development price tsr roche share roche peer group actual exchange rate dec march june sept dec roche share roche peer group dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting consecutive increase dividend dividend proposal approve shareholder dividend payment share nonvoting equity security issue billion swiss franc billion swiss franc result payout ratio base price yearend dividend yield roche share yield nonvoting equity security information roche security give finance report peer group abbott laboratories amgen astrazeneca bayer becton dickinson biogen idec bristolmyers squibb elililly glaxosmithkline johnson johnson merck novartis pfizer sanofiaventis scheringplough takeda wyeth finance report roche group financial review information share nonvoting equity security information share nonvoting equity security chf chf change basic eps dilute eps core eps equity attributable roche shareholder share dividend share detail refer note consolidated financial statement finance report financial risk valueatrisk earningsatrisk analysis tool valueatrisk var calculation indicate range value respective asset liability fluctuate certain probability certain time period hold period var measure statistical measure implicitly assume value change recent past indicative value change future market shock include calculation extent occur observation period group use statistically relevant observation period apply hold period reflect time period require change respective risk exposure deem appropriate long hold period probability high value change increase var measure earningsatrisk ear equivalent var methodology potential value change indicate potential change profit loss certain probability certain time period constraint limitation apply methodology var ear figure interest rate risk measure historical simulation approach historical scenario represent price rate change individual instrument specific day period past year financial instrument fully revalue valuation model total change value earning determine var ear calculation base confidence level hold period trading day group predict future market movement var ear figure give represent actual loss expect incur financial asset liability possible bad loss period state consider effect favourable change market rate foreign exchange risk group exposure movement foreign currency affect net income financial position express swiss franc summarise follow key figure comment growth continue business change local currency change chf sale operating profit exceptional item finance report roche group financial review exchange rate swiss franc december average december average usd eur gbp jpy average dollar euro slightly strengthen swiss franc compensate weak yen consequently difference sale growth operate profit growth express swiss franc local currency absolute term sensitivity group sale continue business movement dollar swiss franc swiss franc approximately million swiss franc correspond sensitivity euro yen approximately million swiss franc million swiss franc respectively group pursue strategy continuously lock favourable development foreign exchange rate enter derivative contract increase hedging activity associate strong sale growth group foreign exchange transaction var increase compare low exposure year end absolute term remain low level foreign exchange risk december december mchf mchf change var monetary position interest rate risk interest rate risk arise movement interest rate adverse effect group net income financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument appropriate group use financial derivative swap manage interest rate risk group unwound fair value hedge fixedrate capital market debt lead increase interest rate var effect partly compensate debt reduction billion swiss franc redemption outstanding bank debt partial conversion lyon convertible note effect high liquid fund interest rate var small instrument short duration comparatively small risk repricing refinancing contain reasonable level earningsatrisk ear increase mainly result liquid fund hold short interest rate commitment generally high interest rate level allow room downward change interest rate interest rate risk december december mchf mchf change var instrument sensitive interest rate ear instrument sensitive interest rate finance report roche group financial review market risk financial asset liability change market value financial asset liability affect net income financial position group market risk arise movement stock price interest rate foreign exchange rate group financial asset hold highly liquid bond money market instrument equity allocation group portfolio cash marketable security billion swiss franc total cash marketable security figure remain stable compare billion swiss franc total cash marketable security international financial reporting standard roche group international financial reporting standard ifrs report consolidated result international accounting standard board iasb publish number new revise standard interpretation effective group implement january significant change relate roche group financial statement arise ia revise employee benefit particular respect define benefit pension postemployment benefit change implement effective january comparative result havebeen restate change previously publish define benefit plan actuarial gain loss actuarial gain loss recognise immediately record directly equity previously actuarial gain loss certain threshold recognise threshold recognise progressively result change group consolidate balance sheet accurately represent fund status plan define benefit plan expect return plan asset interest cost group report expect return plan asset interest cost define benefit plan financial income financing cost respectively previously report divisional operating result change presentation align report group result closely internal management organisation structure detail change give note consolidated financial statement supplementary presentation material investor update hold june available investor relation section group website wwwrochecom finance report roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item major legal case operating profit associate company financial income financing cost profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest continue earning share nonvoting equity security business group basic chf diluted chf finance report roche group roche group consolidate financial statement consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item major legal case operating profit associate company financial income financing cost profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest continue earning share nonvoting equity security business group basic chf diluted chf disclose note income statement restate follow change ifrs adopt effective january reconciliation previously publish income statement provide note finance report roche group roche group consolidate financial statement consolidate balance sheet million chf december december noncurrent asset property plant equipment goodwill intangible asset associate company financial longterm asset longterm asset defer income tax asset postemployment benefit asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer income tax liability postemployment benefit liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable minority interest total equity disclose note balance sheet restate follow change ifrs adopt effective january reconciliation previously publish balance sheet provide note finance report roche group roche group consolidate financial statement consolidated cash flow statement million chf year end december cash flows operating activity cash generate operation increase decrease work capital major legal case payment define benefit postemployment plan utilisation restructure provision utilisation provision operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset disposal product business combination divestment discontinue business divestment subsidiarie interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue longterm debt instrument repayment redemption longterm debt instrument increase decrease longterm debt transaction equity instrument increase decrease shortterm borrowing interest dividend pay exercise equitysettle equity compensation plan genentech share repurchase finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december finance report roche group roche group consolidate financial statement consolidate statement recognise income expense million chf year end december availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation define benefit postemployment plan actuarial gain loss limit asset recognition income taxis item take directly transfer equity net income recognise directly equity net income recognise income statement total recognise income expense attributable roche shareholder minority interest total effect change accounting policy attributable roche shareholder minority interest total disclose note statement recognise income expense restate follow change ifrs adopt effective january reconciliation previously publish statement recognise income expense provide note finance report roche group roche group consolidate financial statement consolidate statement change equity millions chf roche minority shareholder interest total year end december january previously report change accounting policy january restate net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech share repurchase convertible debt instrument change minority interest december year end december january net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech share repurchase convertible debt instrument change minority interest december finance report note roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve issue board director february subject approval annual general meeting shareholder march preparation consolidate financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure ofcontingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change change accounting policy arise application new revise standard interpretation apply retrospectively specify transitional requirement particular standard interpretation retrospective application require result comparative period opening balance period restate new accounting policy apply case transitional requirement particular standard interpretation specify change apply prospectively prospective application require new accounting policy apply result current period comparative period restate addition comparative reclassify extend previously report result account presentational change consolidation policy financial statement consolidate financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enterprise obtain benefit fromit activity control normally evidence roche holding ltd own directly indirectly vote right potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control thegroup company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate investment associate company account equity method company group exercise power exercise significant influence control normally evidence group own voting right potential voting right company balance transaction associate company result unrealised income eliminate extent group interest associate company interest joint venture report linebyline proportionate consolidation method segment report group primary format segment report business segment secondary format geographical segment risk return group operation primarily determine different product group produce geographical location group operation reflect group management organisational structure internal financial reporting system finance report roche group note roche group consolidate financial statement determination group business geographical segment base organisation unit information report group management group division pharmaceutical diagnostic pharmaceutical division subdivision roche pharmaceutical genentech chugai subdivision separate management reporting structure pharmaceutical division consider separately reportable business segment vitamin fine chemical business consumer health otc business previously separately reportable business segment divest present discontinued business certain headquarter activity report corporate consist corporate headquarters include corporate executive committee corporate communication corporate human resource corporate finance include treasury taxis pension fund management corporate legal corporate safety environmental service group geographical segment determine geographical location similarity economic environment transfer price business segment set arm length basis divisional asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory segment liability consist liability provision reasonably attribute report business segment nonsegment asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie principally cash marketable security investment debt capital expenditure comprise addition goodwill intangible asset property plant equipment include arise business combination foreign currency translation group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity defer equity consolidation asset liability group company functional currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity disposal foreign entity identify cumulative currency translation difference equity relate foreign entity recognise income gain loss divestment revenue cost sale sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude sale value add taxis revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid united states similar rebate country deduct sale record deduction account receivable accrue liability provision estimate base analyse exist contractual legislativelymandate obligation historical trend group experience revenue record earn service perform necessary single transaction split separately identifiable component reflect substance transaction conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale include correspond direct production cost relate production overhead good sell service render startup cost validation achievement normal production capacity expense incurred finance report roche group note roche group consolidate financial statement royalty income expense royalty income expense recognise accrual basis royalty expense directly link good sell include cost sale royalty expense include general administration research development addition internal research development activity group party inlicense similar arrangement alliance partner furthermore group acquire inprocess research development asset business combination purchase specific asset internal research cost charge income incur internal development cost capitalise intangible asset identifiable asset complete generate probable future economic benefit cost asset measure reliably group currently internal development cost qualify capitalisation intangible asset internal development cost charge income incur criterion recognition asset meet inprocess research development asset acquire inlicense arrangement business combination separate purchase capitalise intangible asset describe available use intangible asset amortise straightline basis period expect benefit review impairment balance sheet date license milestone upfront receipt payment certain group company receive party upfront milestone similar payment relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence feesfor subsequent deliverable initially report deferred income recognise revenue income earn period development collaboration manufacturing obligation payment group company party associate company item capitalise intangible asset receipt payment consolidate subsidiary genentech chugai roche group subsidiary eliminate consolidation taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future deferred income tax asset liability recognise temporary difference tax basis asset liability carry amount financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy sametaxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate finance report roche group note roche group consolidate financial statement discontinue business noncurrent asset hold sale discontinue business component group business represent separate major line business geographical area operation subsidiary acquire exclusively view resale reclassification discontinue business occur disposal operation meet criterion classify hold sale early disposal group group assets dispose group single transaction withthe liability directly associate asset transfer transaction asset liability disposal group reclassify held sale value recover principally sale continue use disposal group available sale current condition sale highly probable immediately classification hold sale measurement asset liability disposal group update accordance applicable accounting policy initial reclassification hold sale disposal group recognise low carrying fair value cost sell impairment loss initial classification hold sale include income statement employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned liability longterm employee benefit discount account time value money material pension postemployment benefit employee cover define benefit define contribution postemployment plan sponsor group company group contribution define contribution plan charge appropriate income statement head operating result year relate accounting reporting define benefit plan base recent actuarial valuation define benefit obligation service cost calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corporate bond country concern past service cost allocate average period benefit vested current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate business segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss consist difference assumption actual experience effect change actuarial assumption record directly equity pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly equity equity compensation plan certain employee group participate equity compensation plan include separate plan genentech chugai fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record subsequent cash flow exercise vested award record increase equity cashsettle plan liability record measure fair value balance sheet date movement fair value record appropriate income statement head operating result subsequent cash flow exercise vested award record reduction liability finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate item estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incurred borrowing cost capitalise lease group lessee lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt asset acquire finance lease depreciate accordance group policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method lease substantially risk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease group lessor assets subject finance lease report receivables equal net investment lease asset subject operating lease report property plant equipment lease income finance lease recognise term lease base effective interest rate method lease income operating lease recognise lease term straightline basis business combination goodwill business combination account purchase method accounting cost acquisition consideration give exchange control identifiable asset liability contingent liability acquire company consideration include cash pay plus fair value date exchange asset give liability incur assume equity instrument issue group cost acquisition include directly attributable cost acquire net asset identifiable asset liability contingent liability initially recognise fair value group acquire ownership acquire company minority interest record minoritys proportion fair value acquire net asset goodwill record surplus cost acquisition group interest fair value acquire net asset goodwill fair value adjustment record asset liability acquire company record functional currency company goodwill amortise assess possible impairment balance sheet date additionally test annually impairment goodwill arise investment associate company surplus cost investment group share fair value net identifiable asset goodwill record investment associate company finance report roche group note roche group consolidate financial statement intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination fair value allocate acquisition account intangible asset amortise useful life straightline basis beginning point available use estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review amortisation impairment intangible asset present separately income statement materiality amount order fairly present group result impairment property plant equipment intangible asset evidence asset impair recoverable asset calculate impairment assessment carry addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying carry reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy impairment goodwill impairment assessment goodwill carry annually goodwill allocate cashgenerating unit describe note recoverable cashgenerate unit high fair value cost sell value use carrying impairment carrying record methodology impairment testing describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility borrowing cost include cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record difference carry recoverable objective evidence group able collect amount trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience longterm account receivable discount account time value money material provision sale return sale chargeback report provision accrue liability respectively cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition cash flow statement finance report roche group note roche group consolidate financial statement provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign currency effect arise translation functional currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price use establish estimation technique option pricing model estimate discount value cash flow fair value financial asset liability balance sheet date approximately line report carry value specifically mention note consolidated financial statement financial asset financial asset principally investment include marketable security classify fairvalue throughprofitorloss availableforsale heldtomaturity loan receivables fairvaluethrough profitorloss financial asset classify heldfortrade designate initial recognition heldfortrade financial asset acquire principally generate profit shortterm fluctuation price financial asset designate fairvaluethroughprofitorloss result relevant information eliminate measurement recognition inconsistency heldtomaturity financial asset security fix maturity group intent ability hold maturity loan receivables loan longterm financial asset create group acquire issuer primary market nonderivative financial asset fix determinable payment quote active market financial asset consider availableforsale financial asset initially record fair value include transaction cost asset designate fairvaluethroughprofitorloss exclude transaction cost purchase sale recognise settlement date fairvaluethroughprofitorloss financial asset subsequently carry fair value change fair value record financial income period arise heldtomaturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record equity interest calculate effective interest rate method foreign exchange component availableforsale financial asset sell impair dispose cumulative gain loss previously recognise equity include financial income current period loan receivables subsequently carry amortise cost financial asset assess possible impairment balance sheet date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale financial asset market value original cost net previous impairment consider impaired available forsale financial asset market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment sustained sixmonth period consider objective evidence impairment movement fair value record equity objective evidence impairment asset sell dispose financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry equity difference original cost net previous impairment fair value finance report roche group note roche group consolidate financial statement financial asset derecognise contractual right cash flow asset expire group sell dispose contractual right cash flow include situation group retain contractual right assume contractual obligation pay cash flow party derivative derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income period arise embed derivative recognise separately closely related host contract host contract carry amortise cost hedging purpose hedge accounting hedging relationship type fair value hedge hedge particular risk change fair value recognise asset liability cash flow hedge hedge particular risk change time future cash flow hedge net investment foreign entity hedge particular risk change carry value net asset foreign entity qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk anychange fair value report financial income qualify cash flow hedge hedge instrument record fair value portion change infairvalue effective hedge include equity remain ineffective portion report financial income hedge relationship hedge firm commitment highly probable forecast transaction result recognition nonfinancial asset liability cumulative change fair value hedge instrument record equity include initial carrying value asset liability date recognition qualify cash flow hedge cumulative change fair value hedge instrument record equity include financial income forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income hedge instrument derivative equity case entity dispose cumulative change fair value hedge instrument record equity reclassify income debt instrument debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost effective interest method discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method certain debt instrument designate fairvaluethroughprofitorloss result relevant information eliminate significantly reduce measurement recognition inconsistency debt instrument report fair value base quote price active market movement fair value report financial income debt instrument designate fairvaluethroughprofitorloss disclose note finance report roche group note roche group consolidate financial statement bifurcation carry issue convertible debt instrument initial carry value liability element calculate market interest rate equivalent nonconvertible instrument remainder net proceed allocate equity conversion option report equity defer income tax liability liability element subsequently report amortise cost fairvaluethrough profitandloss designate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet obligation arise respect certain group debt instrument management judgement apply accounting policy application group accounting policy require management judgement apart involve estimate significant effect amount recognise consolidated financial statement management judgement particularly require assess substance transaction complicate structure legal form include limited follow area revenue recognition nature group business sale transaction simple structure sale agreement consist multiple component occur different time group party outlicensing agreement involve upfront milestone payment occur year agreement involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement lease group party leasing arrangement lessee lessor treatment leasing transaction financial statement mainly determine lease consider operate lease finance lease make assessment management look substance lease legal form make judgement substantially risk reward ownership transfer key assumption source estimation uncertainty preparation consolidate financial statement conformity ifrs require management estimate assumption affect application policy report amount asset liability income expense relate disclosure estimate underlying assumption base historical experience factor believe reasonable circumstance result form basis make judgement carry value asset liability readily apparent source actual result differ estimate estimate underlying assumption review ongoing basis change accounting estimate necessary change circumstance estimate base result new information experience change recognise period estimate revise key assumption future key source estimation uncertainty significant risk cause material adjustment carry value asset liability month describe finance report roche group note roche group consolidate financial statement sale allowance group accrual provision expect sale return chargeback rebate include medicaid united states similar rebate country december total million swiss franc estimate base analyse exist contractual legislatively mandate obligation historical trend group experience management believe total accrual provision item adequate base currently available information deduction base management estimate subject change well information available change arise impact accrual provision recognise balance sheet future period consequently level sale recognise income statement future period property plant equipment intangible asset include goodwill group property plant equipment carry value million swiss franc disclose note goodwill carry value million swiss franc note intangible asset carry value million swiss franc note asset review annually impairment describe assess impairment exist estimate future cash flow expect result use asset eventual disposal actual outcome vary significantly estimate discount future cash flow factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment pension postemployment benefit group employee participate post employment define benefit plan calculation recognise asset liability plan base statistical actuarial calculation particular present value define benefit obligation impact assumption discount rate arrive present value future pension liability assumption future increase salary benefit furthermore group independent actuary use statistically base assumption cover area future withdrawal participant plan estimate life expectancy december present value group define benefit obligation million swiss franc fund plan million swiss franc unfunded plan note actuarial assumption differ materially actual result change market economic condition high low withdrawal rate long short life span participant change factor assess difference impact asset liability recognise balance sheet future period legal provision group company party legal proceeding significant matter describe note legal provision december total million swiss franc disclose note additional claim cover exist provision insurance assurance increase scope matter future lawsuit claim proceeding investigation material change arise impact provision recognise balance sheet future period environmental provision group provision environmental remediation cost december total million swiss franc disclose note material component environmental provision consist cost fully clean refurbish contaminate site treat contain contamination certain site future remediation expense affect number uncertainty include limited detection previously unknown contaminate site method extent remediation percentage waste material attributable group remediation site relative attributable party financial capability potentially responsible party management believe total provision environmental matter adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue effect resolution environmental matter result operation predict uncertainty concern time future expenditure change arise impact provision recognise inthe balance sheet future period finance report roche group note roche group consolidate financial statement income taxis december net liability current income taxis million swiss franc net liability defer income taxis million swiss franc disclose note significant estimate require determine current defer asset liability income taxis estimate base interpretation exist tax law regulation management believe estimate reasonable recognise liability income taxrelate uncertainty adequate internal external factor favourable unfavourable effect income tax asset liability factor include limited change tax law regulation andor rate change interpretation exist tax law regulation future level research development spending change overall level pretax earning change arise impact asset liability recognise balance sheet future period change accounting policy group adopt certain new revise international financial reporting standard interpretation effective january description change material group effect consolidated financial statement give ia revise employee benefit matter revise standard allow actuarial gain loss define benefit plan record directly equity case adjustment arise limit recognition asset define benefit plan record directly equity revise standard require retrospective application addition group report expect return plan assetsand interest cost define benefit plan financial income financing cost respectively correspond postemployment benefit asset liability include nonsegment asset liability segment report change presentation align report group result closely internal management organisation structure information group pension postemployment benefit give note presentation income statement income statement year end december restate follow change ifrs adopt effective january addition group certain presentational change improve comparability result healthcare company allow reader accurate assessment sustainable earning capacity group change apply retrospectively list support cost lease diagnostic instrument report cost sale instead market distribution million swiss franc million swiss franc restate income statement year end december millions chf originally ias group publish revise restate sale operating item operating profit financial nonoperate item profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest earning share nonvoting equity security basic group chf diluted group chf finance report roche group note roche group consolidate financial statement presentation balance sheet balance sheet december restate result change ifrs adopt effective january result implementation ias revise postemployment benefit asset million swiss franc lower defer income tax asset million swiss franc high postemployment benefit liability million swiss franc higher defer income tax liability million swiss franc lower restate balance sheet december millions chf originally ias group publish revise restate noncurrent asset current asset total asset noncurrent liability current liability total liability total net asset minority interest equity presentation recognise income expense change equity new revise standard adopt effective january result significant change format content change equity ia revise require retrospective implementation accordingly open equity statement recognise income expense restate restate equity january millions chf originally ias group publish revise restate share capital equity instrument retain earning fair value reserve hedging reserve translation reserve equity attributable roche shareholder minority interest total equity restate recognise income expense year end december millions chf originally ias group publish revise restate net income recognise directly equity net income recognise income statement total recognise net income attributable roche shareholder minority interest total finance report roche group note roche group consolidate financial statement future change ifrs group currently assess potential impact new revise standard effective january group expect new revise standard interpretation significant effect group result financial position expand financial statement disclosure certain area notably ifrs financial instrument disclosure group implement group process evaluate ifrs operating segment effective january financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie group subsidiarie genentech chugai treasury operation operational independence whilst work financial risk management framework consistent rest group information financial risk available annual report genentech chugai financial risk management group govern policy guideline approve senior management policy guideline cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policy guideline cover area cash management investment excess fund raise short longterm debt compliance policy guideline manage segregated function group objective financial risk management contain deem appropriate exposure type financial risk mention order limit negative impact group result financial position group actively measure monitor manage financial risk exposure function pursuant segregationofdutie principle accordance financial risk policy group manage market risk exposure use financial instrument derivative deem appropriate group policy practice enter derivative transaction trade speculative purpose purpose unrelated underlying business foreign exchange risk group operate world expose movement foreign currency affect net income financial position express swiss franc group actively monitor currency exposure appropriate enter transaction aim preserve value asset commitment anticipate transaction group use forward contract foreign exchange option crosscurrency swap hedge certain commit anticipate foreign exchange flow financing transaction transaction exposure arise local currency pay receive transaction denominate foreign currency vary change exchange rate similarly transaction exposure arise net balance monetary asset hold foreign currency group company revenue operating expense primarily local currency local level group company manage exposure necessary mean financial instrument option forward contract addition group treasury monitor total worldwide exposure monthly basis translation exposure arise consolidation foreign currency denominate financial statement group foreign subsidiary effect group consolidated equity show currency translation movement group partially hedge net investment foreign currency take foreign currency loan issue foreign currency denominate debt instrument major translation exposure monitor regularly finance report roche group note roche group consolidate financial statement significant group cash outflow research development production administration denominate swiss franc small proportion group cash inflow swiss franc denominate result increase value swiss franc relative currency adverse impact consolidate net income similarly relative decrease value swiss franc favourable effect result report swiss franc interest rate risk interest rate risk arise movement interest rate effect group net income financial position change interest rate cause variation interest income expense result interestbeare asset liability addition affect market value certain financial asset liability instrument describe follow section market risk financial asset interest rate group major debt instrument fix describe note group use interest rate derivative manage interest rate risk market risk financial asset change market value certain financial asset derivative instrument affect net income financial position group financial longterm asset hold strategic purpose marketable security hold fund management purpose risk loss value manage review prior invest continuous monitoring performance investment change risk profile investment equity bond debenture fix income instrument enter basis guideline regard liquidity credit rating credit risk credit risk arise possibility counterparty transaction unable unwilling meet obligation cause financial loss group trade receivables subject policy active risk management focus assessment country risk credit availability ongoing credit evaluation account monitoring procedure note significant concentration trade receivables counterparty credit risk group large number customer wide geographical spread credit exposure critical country group obtain credit insurance country risk exposure continuously monitor exposure financial asset credit risk control settinga policy limit credit exposure highquality counterpartie regular review credit rating set define limit counterparty appropriate reduce exposure netting agreement isda international swap derivative association master agreement sign respective counterpartie maximum exposure credit risk result financial activity consider net agreement equal carrying financial asset plus positive fair value derivative instrument credit exposure diversify different counterpartie december group combine trade account receivable balance national wholesale distributor amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss franc represent group consolidated trade account receivable billion swiss franc represent liquidity risk group company require sufficient availability cash meet obligation individual company generally responsible cash management include shortterm investment cash surplus raise loan cover cash deficit subject guidance group certain case approval group level group maintain sufficient reserve cash readily realisable marketable security meet liquidity requirement times addition strong international creditworthiness group provide ability efficiently use international capital market financing purpose group unused committed credit line financial institution total billion swiss franc include syndicate credit facility billion euro bank commitment line billion japanese yen chugai finance report roche group note roche group consolidate financial statement segment information divisional information millions chf roche pharmaceutical genentech chugai segment revenue segment revenuesdivisional sale interdivisional sale divisional sale party segment result operate profit exceptional item major legal case segment resultsoperate profit segment asset liability divisionalsegment asset nonsegment asset total asset divisional liability segment liability segment liability nonsegment liability total liability segmental expense information research development cost equity compensation plan expense restructuring expense capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset income associate company investment associate company finance report roche group note roche group consolidate financial statement pharmaceutical diagnostic division division corporate group finance report roche group note roche group consolidate financial statement information geographical segment millions chf sale party destination segment asset capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total genentech effective september group acquire majority interest approximately genentech inc biotechnology company united states june group exercise option acquire remain share genentech june point genentech own subsidiary group july october march group complete public offering genentech common stock reduce group majority interest group ownership genentech decrease conversion redemption lyon dollar exchangeable note genentech issue additional share common stock connection equity compensation plan issue additional share purpose affect group percentage ownership interest affiliation agreement group genentech provide thing genentech establish stock repurchase programme maintain group percentage ownership interest genentech december group interest genentech finance report roche group note roche group consolidate financial statement common stock genentech publicly trade list new york stock exchange symbol dna genentech prepare financial statement conformity accounting principle generally accept united states gaap file quarterly basis securities exchange commission sec difference ifrs gaap certain consolidation entry difference requirement international financial reporting standard ifrs gaap difference genentech standalone financial result gaap basis financial result genentech consolidate roche group accordance ifrs reconciliation genentech result usd chf usd chf million million million million operating income gaap basis redemption cost equity compensation plan expense gaap basis special litigation item operating income nonus gaap basis add deduct difference consolidation entry add redemption cost equity compensation plan expense ifrs basis capitalise inprocess research development difference consolidation entry operating profit exceptional item ifrs basis add deduct exceptional item major legal case segment resultoperate profit ifrs basis add deduct nonoperate item ifrs basis financial income financing cost income taxis net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis translate usd chf usd chf effective january group implement ifrs sharebase payment ifrs financial statement matter standard require fair value equity compensation plan award employee estimate grant date record expense vest period expense charge appropriate income statement head standard require retrospective application certain transitional requirement pretax expense million dollar million swiss franc relate plan genentech record million dollar million swiss franc impact transitional requirement amount indicative future expense plan effective january genentech implement statement financial accounting standard sharebase payment fas gaap financial statement matter require company report gaap recognise compensation expense plan different date application measurement requirements transitional arrangement fas ifrs expense record genentech gaap financial statement equity compensation plan expense record roche group ifrs financial statement plan finance report roche group note roche group consolidate financial statement group implement ias revise intangible asset ifrs financial statement matter revise standard typically result intangible asset recognise inlicense arrangement similar research development alliance genentech gaap financial statement expenditure usually record research development expense difference ifrs gaap relatively minor impact genentech share repurchase april genentechs board director approve extension exist stock repurchase programme authorise genentech repurchase million share genentech common stock total billion dollar june programme inception genentech repurchase approximately million share total approximately billion dollar genentech repurchase common stock worth million dollar million swiss franc million dollar million swiss franc manufacturing agreement lonza effective december genentech sell whollyowne subsidiary genentech espaa include manufacturing facility porrio spain lonza group ltd lonza million dollar million dollar receive cash remain balance receive lonza series payment year agreement genentech enter shortterm supply contract lonza production avastin portion production capacity porrio facility loss divestment genentech espaa millions chf consideration cash present value unsecured receivables lonza total consideration net asset dispose property plant equipment net asset loss divestment time genentech enter supply agreement manufacture certain genentech product lonzas facility construction singapore currently expect receive food drug administration fda licensure genentech commit fund precommissione production qualification cost facility fda licensure genentech commit purchase product successfully manufacture facility period year commission facility estimate total cost pre postcommissione commitment approximately million dollar genentech receive exclusive option purchase lonza singapore facility period year fda licensure purchase price million dollar regardless purchase option exercise genentech oblige milestone payment million dollar certain performance milestone meet facility construct genentech enter loan agreement lonza advance million dollar lonza construction singapore facility majority expect advanced majority fund advanced lonza lonzas securitisation obligation mutually agree party genentech exercise option purchase facility outstanding advance offset purchase price genentech exercise purchase option advance offset supply purchase finance report roche group note roche group consolidate financial statement oceanside biologics manufacturing facility june genentech complete purchase oceanside biologic manufacturing facility san diego california biogen idec purchase cost include closing cost million swiss franc acquisition tanox november genentech announce plan acquire control interest tanox inc tanox publicly own company list nasdaq symbol tnox tanox biotechnology company base houston texas specialise discovery development biotherapeutic base monoclonal antibody technology genentech tanox work collaboration novartis develop commercialise xolair expect purchase consideration exclude transaction cost million dollar cash fund provide genentech cash hand thetime closing january transaction approve tanoxs shareholder transaction subject regulatory clearance expect complete half leasing arrangement quarter genentech pay million dollar buy lease obligation respect manufacturing facility vacaville california certain building south san francisco site december genentech enter master lease agreement slough ssf llc slough development property adjacent genentechs south san francisco site development include total building subject separate agreement contemplate master lease agreement slough developer construct building shell building genentech finish interior build laboratory office space applicable construction building complete point lease term building deem begin construction final building expect complete lease term expire year occupation final building genentech fiveyear renewal option building option purchase building different date genentech right refusal respect build entire development slough consider sell development december base status development date total carrying value property plant equipment agreement include tenant improvement million swiss franc carry value lease obligation million swiss franc estimate total future minimum lease payment anticipate entire master lease agreement show estimate total future minimum lease payment slough lease millions chf total minimum principal ground lease interest lease payment year year year total matter detail genentech legal case give note detail genentechs equity compensation plan give note detail genentechs senior note give note chugai effective october roche group chugai complete alliance create lead research drive japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai finance report roche group note roche group consolidate financial statement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange difference ifrs jgaap certain consolidation entry difference requirement international financial reporting standard ifrs jgaap difference chugais standalone financial result jgaap basis financial result chugai consolidated roche group accordance ifrs acquisition roche interest chugai treat business combination ifrs jgaap alliance treat merger chugai nippon roche jgaap result chugai include goodwill fair value adjustment record roche result quantify table acquisition accounting include roche fair value adjustment impact net income need add minority interest calculation roche ifrs result roche ifrs result depreciation property plant equipment calculate straightline method chugais jgaap result reduce balance method additionally certain income expense notably restructure cost require jgaap report extraordinary item chugais jgaap result extraordinary item report operate profit line roche ifrs result item normally include operating profit treat extraordinary exceptional item restructure cost million swiss franc million swiss franc difference ifrs jgaap relatively minor impact reconciliation chugai result jpy chf jpy chf billion million billion million operate profit jgaap basis depreciation basis difference classification extraordinary item difference consolidation entry chugai operate profit exceptional item acquisition accounting impact ifrs basis depreciation property plant equipment amortisation intangible asset arise business combination chugai operate profit exceptional item ifrs basis add deduct exceptional item major legal case chugai segment resultoperate profit ifrs basis add deduct corporate nonoperating item ifrs basis gain settlement define benefit plan financial income financing cost income taxis net income ifrs basis minority interest calculation add acquisition accounting impact net income net income exclude acquisition accounting minority interest percentage average year income applicable minority interest ifrs basis translate jpy chf jpy chf finance report roche group note roche group consolidate financial statement dividend dividend distribute party hold chugai share include special dividend total million swiss franc million swiss franc record minority interest note dividend pay chugai roche eliminate consolidation intercompany item restructure production facility february chugai announce restructure production facility exist plant integrate facility year restructure plant kagamiishi sell half total restructuring cost include loss disposal kagamiishi plant million swiss franc show extraordinary loss chugaisjgaap financial statement pension postemployment benefit second half chugai return employee pension fund japanese government result settlement gain million swiss franc accordance group management organisational structure report general administration expense corporate business segment result show extraordinary gain chugais jgaap financial statement matter detail chugais equity compensation plan give note detail series chugai pharmaceutical unsecured convertible bond include conversion year give note royalty operating income royalty operating income million chf pharmaceutical diagnostic group royalty income income outlicense agreement gain disposal product total royalty operating income income outlicense agreement certain group company receive party upfront milestone similar payment relate sale licensing product technology revenue associate performance milestone recognise base achievement milestone define respective agreement revenue upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation gain disposal product continuous realignment product portfolio group periodically dispose product line long consider core product priority product development portfolio proceed reinveste group inlicense arrangement research development alliance collaboration finance report roche group note roche group consolidate financial statement major legal case income expense major legal case million chf roche pharmaceutical legal case genentech legal case diagnostic legal case total income expense major legal case continue business discontinue business vitamin case group total income expense major legal case continue business disclose separately income statement materiality amount order fairly present group result total net cash outflow major legal case year million swiss franc million swiss franc roche pharmaceutical legal case roche diagnostic gmbh rdg smithkline beecham cork ltd party arbitration concern rdgs termination carvedilol license agreement amend relate licensing comarkete carvedilol rdg submit claim damage arbitration tribunal zurich submit counterclaim assert invalidity rdgs termination claim damage base development current arbitration settlement negotiation group increase exist provision million swiss franc development require change provision record group total provision record rdg disclose seriously prejudice rdgs position matter genentech legal case june genentech announce los angeles county superior court jury vote award city hope medical center city hope approximately million dollar compensatory damage base find breach agreement genentech city hope june jury vote award city hope million dollar punitive damage case september genentech file notice appeal jury verdict damage awards california court appeal october court appeal affirm verdict damage award respect october genentech announce seek review california supreme court discretion case review november genentech file petition review california supreme court february california supreme court grant petition appeal california supreme court fully brief genentech wait assign oral argument date provision classify longterm record damage award appeal process interest accrue total damage simple annual rate follow judgement interest million swiss franc million swiss franc record time cost provision financing cost october genentech enter arrangement withthirdparty insurance company post surety bond connection judgement arrangement genentech pledge million dollar cash investment secure bond december increase million dollar million dollar equivalent million swiss franc december report restrict cash financial long term asset note october genentech receive subpoena united states department justice request document relate promotion rituxan prescription product approve treatment relapse refractory lowgrade follicular cdpositive bcell nonhodgkin lymphoma genentech cooperating associate investigation genentech advise civil criminal nature government call expect current genentech employee appear grand jury connection investigation provision record respect litigation outcome matter determine time finance report roche group note roche group consolidate financial statement april medimmune inc medimmune file lawsuit genentech city hope national medical center celltech ltd district court central district california los angeles lawsuit relate patent cabilly patent coowne genentech city hope national medical center medimmune company license pay royalty lawsuit include claim violation antitrust patent unfair competition law january district court grant summary judgement medimmunes antitrust andunfair competition claim april district court grant motion dismiss remain claim case october court appeal federal circuit affirm judgement district court respect november medimmune file petition supreme court seek review decision dismiss certain claim supreme court grant medimmunes petition oral argument case supreme court occur october january supreme court issue decision reverse federal circuit decision remand case low court proceeding decision address issue medimmune patent contract claim forward federal court express opinion merit claim provision record respect litigation outcome matter determine time request file party reexamination cabilly patent july patent trademark office order reexamination patent september patent office issue initial nonfinal office action reject claim patent genentech file response november patent office act response second reexamination request patent file december party january patent office grant reexamination request june reexamination combine patent office single reexamination august patent office issue nonfinal office action merge proceeding reject claim cabilly patent base issue raise reexamination request genentech file response october patent office act response cabilly patent expire relate method genentech certain antibody antibody fragment cell dna method genentech license cabilly patent company derive significant royalty licence claim cabilly patent remain valid enforceable reexamination process examination process ongoing provision record respect litigation final outcome matter determined time july genentech employee employment end april file nonpublic qui tam complaint seal united states district court district maine genentech biogen idec allege violation false claim act retaliatory discharge employment december united states district court file notice election decline intervention lawsuit complaint subsequently unseal genentech serve january genentech file motion dismiss complaint december magistrate judge issue recommend decision motion magistrate judge recommend grant genentech motion dismiss employee qui tam claim recommend deny genentech motion solely employee claim retaliatory discharge employment party file objection district court judge concern portion magistrate judge recommend decision review district court judge seek provision record respect litigation potential outcome determine time march kourosh dastghieb file lawsuit genentech district court eastern district pennsylvania lawsuit relate dastghiebs claim base relationship genentech mid entitle profit proceed genentech lucentis product dastghieb assert multiple claim monetary damage include claim unjust enrichment theory entitle entire net present value lucentis claim approximately billion dollar billion dollar november unanimous jury rule dastghieb favour genentech claim final judgement enter genentechs favour plaintiff file motion challenge judgement set hear early provision record respect litigation potential outcome determine time finance report roche group note roche group consolidate financial statement genentechs annual report quarterly sec filing contain detailed disclosure litigation matter require gaap include detail matter include information litigation currently significant matter refer diagnostic legal case provision certain litigation arbitration matter diagnostic division increase million swiss franc development require change tothe provision record group october applera corporation applera file suit group superior court california file notice arbitration american arbitration association superior court lawsuit arbitration demand claim concern interpretation enforcement contract group applera commercialisation polymerase chain reaction pcr technology claim seek termination certain contract declaration right obligation contract monetary damage relief unspecified allege breach agreement party december group file response arbitration proceeding day group respond appleras complaint superior court proceeding petitioning court compel arbitration claim allege applera stay lawsuit pende completion arbitration october court appeal state california rule petition compel arbitration grant remand case superior court direction grant petition group announce settlement agreement reach applera regard outstanding litigation arbitration relate contractual relationship involve right commercialisation polymerase chain reaction pcr technology group file suit promega corporation promega allege patent infringement breach licence agreement relate polymerase chain reaction pcr technology district court northern district california decide patent concern unenforceable reject breach licence claim november group notify promega file nonpublic qui tam action group district court eastern district west virginia march complaint file false claim act allege federal government overcharge purchase pcr enzyme product july federal government notify court decision intervene promegas complaint november court order complaint unseal group file motion dismiss complaint august thecourt dismiss complaint prejudice september group announce settlement agreement reach promega regard outstanding litigation relate polymerase chain reaction pcr technology vitamin case follow settlement agreement department justice pricing practice vitamin market overall settlement agreement class action suit bring buyer bulk vitamin group record provision respect vitamin case provision group well estimate time total liability arise take account currency movement time value money provision legal fee record separately group record additional provision base development litigation settlement negotiation europe january district columbia circuit court appeals rule class action litigation bring behalf nonus purchaser bulk vitamin group manufacturer nonus plaintiff bring claim court antitrust law allege damage suffer transaction outside united states june supreme court united states nullify decision district columbia circuit court appeal supreme court remand case low court review alternative argument permit claim proceed united states remand june panel district columbia circuit court appeal rule unanimously court jurisdiction plaintiff claim affirm initial dismissal complaint october plaintiff petition supreme court discretionary review january supreme court finance report roche group note roche group consolidate financial statement issue order deny plaintiff petition march plaintiff file motion trial court seek relief final judgement plaintiff advance european union law claim trial court trial court deny motion plaintiff time appeal trial court rule expired group consider matter closed group seek resolve remain outstanding issue time final amount involve uncertain remain provision consider shortterm cash outflow expect arise discount time value money consider material case litigation negotiation progress possible ultimate liability different provision currently record financial income financing cost financial income million chf year end december gain sale equity security loss sale equity security dividend income gain loss equity derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security net gain loss financial asset fairvaluethroughprofitorloss writedown impairment longterm loan net interest income income debt security expect return plan asset define benefit plan foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total financial income financing cost million chf year end december interest expense amortisation discount debt instrument gain loss interest rate derivative net net gain loss financial liability fairvaluethroughprofitorloss time cost provision interest cost define benefit plan total financing cost finance report roche group note roche group consolidate financial statement net financial income million chf year end december financial income financing cost net financial income financial result treasury management financial result pension management net financial income net gain loss financial liability fairvaluethroughprofitorloss includes change fair value attributable change liabilitie credit risk component calculate compare difference present value future cash flow bond discount swap libor yield curve market price bond major credit spread movement relative swap yield curve change fair value attributable change liabilitie credit risk component zero loss million swiss franc cumulative change fair value attributable change credit risk issuance instrument gain million swiss franc gain million swiss franc interest expense liability fairvaluethroughprofitorloss million swiss franc million swiss franc income taxis income tax expense millions chf current income taxis adjustment recognise current tax prior period defer income taxis total charge income taxis group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate million chf average expect tax rate tax effect utilisation previously unrecognise tax loss nontaxable incomenondeductible expense genentech equity compensation plan difference continue business exceptional item effective tax rate profit income tax profit income tax tax taxis rate tax taxis rate roche exclude genentech chugai genentech chugai continue business exceptional item effective tax rate major legal case group effective tax rate finance report roche group note roche group consolidate financial statement income tax asset liability millions chf current income taxis current income tax asset current income tax liability net current income tax asset liability defer income taxis defer income tax asset defer income tax liability net defer income tax asset liability defer income tax asset recognise tax loss carry forwards extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry millions chf year year year total unrecognised tax loss defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable follow item defer income taxis movement recognise net asset liability millions chf property plant equipment temporary intangible asset difference total year end december net defer income tax asset liability january previously report change accounting policy net defer income tax asset liability january restate charge credit income statement charge credit equity recognise gain loss charge credit equity equity compensation plan transaction shareholder acquisition glycart currency translation effect net defer income tax asset liability december finance report roche group note roche group consolidate financial statement property plant equipment temporary intangible asset difference total year end december net defer income tax asset liability january charge credit income statement charge credit equity recognise gain loss charge credit equity equity compensation plan transaction shareholder currency translation effect net defer income tax asset liability december business combination net cash outflow acquisition subsidiary associate company millions chf glycart acquisition total net cash outflow acquisition amount net cash balance acquire company acquisition acquisition november genentech announce plan acquire control interest tanox inc biotechnology company transaction expect close thefirst half subject regulatory approval describe note acquisition glycart effective july group acquire control interest glycart biotechnology ltd glycart privatelyowne biotechnology research company base schlieren zurich switzerland glycart report roche pharmaceutical business segment purchase consideration pay million swiss franc allocate follow glycart acquisition net asset acquire millions chf carrying value carry value prior acquisition acquisition goodwill intangible asset inprocess research development intangible asset core technology property plant equipment defer income taxis cash net asset liability total goodwill recognise result premium pay acquisition represent synergy obtain group exist business utilise acquire core technology intangible asset core technology amortise straightline basis year begin august intangible asset inprocess research development amortise useful life straightline basis beginning point available use subsequent acquisition glycart contribute net expense million swiss franc roche pharmaceutical business result glycart acquire january revenue group unchanged group net income lower million swiss franc compare report result finance report roche group note roche group consolidate financial statement discontinue business profit discontinued business million chf consumer vitamin consumer vitamin health fine health fine otc chemical total otc chemical total segment revenue expense operate profit exceptional item operating profit financing cost profit taxis income taxis business result gain loss disposal income taxis profit disposal profit discontinue business earning share nonvoting equity security basic chf diluted chf asset liability discontinue business million chf consumer vitamin consumer vitamin health fine health fine otc chemical total otc chemical total property plant equipment longterm asset current asset total asset provision noncurrent liability current liability total liability net asset significant cash flow discontinue business million chf consumer vitamin consumer vitamin health fine health fine otc chemical total otc chemical total operating cash flow major legal case proceed disposal total significant cash inflow outflow finance report roche group note roche group consolidate financial statement divestment consumer health otc business july group announce sale roche consumer health global otc overthecounter medicine business bayer group agreement bayer majority local business transfer bayer end divestment remain measure term roche consumer health sale party complete term agreement majority cash proceed total million swiss franc transfer group january addition group receive million swiss franc half remain divestment complete calculation final amount arise agree purchase price adjustment mechanism complete result million swiss franc transfer bayer effect net income transfer amount concerned cover accrual initial calculation gain disposal profit disposal consist release million swiss franc respect certain accrual andprovision long require business result include remain roche consumer health transfer bayer significant cash flow receipt divestment proceed receive bayer describe divestment vitamin fine chemical business effective september group complete sale global vitamin fine chemical business vfc business dutch company dsm follow sale vfc business certain asset liability vitamin fine chemical division mainly associate vitamin case remain group group dsm sign indemnity cooperation agreement group provide dsm certain indemnity guarantee connection vitamin case addition group give dsm certain indemnity respect anyremedial action site vfc business require environmental law arrangement place utilisation certain asset certain purchasing contract adopt dsm preferred supplier pharmaceutical ingredient arrangement group guarantee purchase period year begin january product sale value total million euro group reimburse dsm unutilised amount arrangement consist certain residual obligation fully accrue profit disposal consist release million swiss franc respect certain accrual provision long require business result include cost million swiss franc million swiss franc aftertax amortisation discount liability employee benefit employee remuneration million chf wage salary social security cost define contribution postemployment plan operating expense define benefit postemployment plan equity compensation plan employee benefit employee remuneration include operating result expect return plan asset define benefit postemployment plan interest cost define benefit postemployment plan total employee remuneration finance report roche group note roche group consolidate financial statement employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit charge employee benefit operating result include relevant expenditure line function expect return plan asset interest cost define benefit plan include financial income financing cost respectively note pension postemployment benefit group objective provide attractive competitive postemployment benefit employee atthe time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement economic condition country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan group potential obligation relatively minor relatively remote possibility arise consequently group postemployment benefit plan classify define benefit plan purpose financial statement define contribution plan define contribution plan typically consist payment employee group fund administer party payment group million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution define benefit plan group major define benefit plan locate switzerland united states germany united kingdom japan plan usually establish trust independent group fund payment group employee case notably major define benefit plan germany plan unfunded group pay pension retire employee directly financial resource current past service cost charge appropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate business segment expect return plan asset interest cost charge financial income financing cost respectively actuarial gain loss record directly equity recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit recognition asset define benefit plan record directly equity finance report roche group note roche group consolidate financial statement define benefit plan expense millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total current service cost past service cost gain loss curtailment gain loss settlement total operating expense expect return plan asset interest cost total financial income expense total expense recognise income statement funding group define benefit plan oversee corporate level qualified independent actuary carry valuation regular basis major plan annually balance sheet date fund plan usually trust independent group finance net assetliability recognise group balance sheet correspond overunder funding plan adjust unrecognised past service cost unfunded plan group meet pension obligation directly financial resource liability define benefit obligation record group balance sheet pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit present value future refund plan reduction future contribution plan cumulative unrecognised past service cost amount recognise balance sheet postemployment benefit predominantly noncurrent report noncurrent asset liability define benefit plan fund status december millions chf fund unfunded fund unfunded plan plan total plan plan total fair value plan asset define benefit obligation funding unrecognise past service cost limit asset recognition reimbursement right net recognise asset liability report postemployment benefit asset postemployment benefit liability reimbursement right net recognise asset liability detailed information plan asset define benefit obligation give finance report roche group note roche group consolidate financial statement define benefit plan fair value plan asset millions chf january expect return plan asset actuarial gain loss currency translation effect employer contribution employee contribution benefit pay fund plan past service cost business combination curtailment settlement december invest share equity instrument bond debenture debt instrument property asset total include fair value plan asset thousand group nonvoting equity security fair value million swiss franc thousand nonvoting equity security write option total fair value million swiss franc define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost employee contribution actuarial gain loss currency translation effect benefit pay fund plan benefit pay unfunded plan past service cost business combination curtailment settlement december fund plan unfunded plan cost certain group postemployment plan reimburse government programme reimbursement right report longterm asset note total million swiss franc december million swiss franc movement reimbursement right primarily consist currency translation effect million swiss franc finance report roche group note roche group consolidate financial statement actuarial assumption actuarial assumption unbiase mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter salary benefit level interest rate return investment cost medical benefit group operate define benefit plan country actuarial assumption vary base local economic social condition demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity mortality table major scheme germany heubeck table japan national census life table switzerland swiss bvg united kingdom nonpensioner pac rate year united kingdom pensioner pac rate year united states project rate employee turnover disability early retirement base historical behaviour group company financial assumptionsthese base market expectation period obligation settle range assumption actuarial valuation significant plan areincountrie stable currency interest rate show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate return plan asset expect rate salary increase medical cost trend rate discount rate calculate discount present value define benefit obligation determine reference market yield high quality corporate bond government bond countrie deep market corporate bond currency term bond consistent obligation discount interest cost include income statement calculate multiply discount rate define benefit obligation expect return plan asset base market expectation expect return asset fund plan duration relate obligation take account split plan asset equity bond property investment calculation include assumption concern expect dividend interest income realise unrealised gain plan asset taxis administration cost bear plan base longterm market expectation actual performance continually monitor corporate management longterm nature obligation assumption matter return investment necessarily consistent recent historical pattern expect return plan asset include income statement calculate multiplying expect rate return fair value plan asset difference expect return actual return month period actuarial gainloss record directly equity actual return plan asset million swiss franc million swiss franc expect rate salary increase calculate define benefit obligation current service cost include income statement base late expectation historical behaviour group company finance report roche group note roche group consolidate financial statement medical cost trend rate calculate define benefit obligation current service cost include income statement postemployment medical plan account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development united states effect percentage point increase decrease medical cost trend rate show define benefit plan sensitivity medical cost trend rate millions chf current service cost interest cost define benefit obligation funding summary fiveyear summary funding status group define benefit plan show table define benefit plan summary funding status millions chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation increase decrease funding status arise experience adjustment fair value plan asset define benefit obligation increase decrease funding status arise change actuarial assumption fair value plan asset define benefit obligation cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc amount record equity actuarial gain loss recognise statement recognise income expense gain million swiss franc loss million swiss franc cumulative december gain million swiss franc loss million swiss franc addition recognition pension asset limit total present value future refund plan reduction future contribution plan cumulative unrecognised past service cost adjustment arise limit asset recognition record directly equity adjustment million swiss franc zero finance report roche group note roche group consolidated financial statement employee stock option equity compensation benefit group operate equity compensation plan include separate plan genentech chugai effective january group adopt ifrs sharebased payment matter standard require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge appropriate income statement heading expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operate expense share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche performance share plan roche stock appreciation right total equity compensation plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche performance share plan roche stock appreciation right total equity compensation plan total cash inflow outflow equitysettle cashsettle finance report roche group note roche group consolidate financial statement roche longterm group implement new global longterm incentive programme available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan share option plan roche option planaward plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note introduction roche longterm number option grant roche option plan significantly reduce eligible employee receive roche stocksettle stock appreciation right instead roche option plan movement number option outstanding number weight average number weight average option exercise price option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable weighted weight number weight average average number average outstanding year remain exercise exercisable exercise year grant thousands contractual life price chf thousand price chf total genentech stock option planthe genentech stock option plan adopt amend april genentechs shareholder approve equity incentive plan plan allow grant stock option incentive stock option stock purchase right employee director consultant genentech incentive stock option stock purchase right grant plan date option grant nontradable equitysettle award tenyear duration vest phase basis year subject continued employment finance report roche group note roche group consolidate financial statement genentech stock option plan movement number option outstanding number number option weight average option weight average million exercise price usd million exercise price usd outstanding january grant forfeit exercise expired outstanding december exercisable genentech stock option plan term option outstanding december option outstanding option exercisable weighted weight number weight average average number average range exercise price outstanding year remain exercise exercisable exercise usd millions contractual life price usd million price usd total chugai stock acquisition right chugai adopt stock acquisition right programme programme allow grant right employee director chugai right entitle holder purchase chugai share specify exercise price option nontradable equitysettle award tenyear duration vest year chugai stock acquisition right movement number right outstanding number weight average number weight average option exercise price jpy option exercise price jpy outstanding january grant forfeit exercise expired outstanding december exercisable chugai stock acquisition right term right outstanding december right outstanding right exercisable weighted weighted weight average average average number year remain exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy total finance report roche group note roche group consolidate financial statement issue share option issue share option include methodology calculate fair value main input valuation model describe issue share option plan roche genentech stock chugai stock option plan option plan acquisition right number option grant thousand million underlying equity roche nonvoting genentech common chugai share equity security stock block currency swiss franc dollar japanese yen vest period progressively progressively year year year contractual life year year year weight average fair value option issue option pricing model binomial binomial binomial input option pricing model share price grant date exercise price expect volatility expect dividend yield early exercise factor expect exit rate volatility determine reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour chugai grant assume award hold term length insufficient historically observe early exercise behaviour equity compensation plan roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold thousand nonvoting equity security thousand programme operational october year cost plan million swiss franc million swiss franc report relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allow employee purchase genentech common stock low market value grant date purchase date total million share genentech common stock purchase million share result cash inflow million swiss franc million swiss franc year cost plan million swiss franc million swiss franc report relevant expenditure line function finance report roche group note roche group consolidate financial statement roche stocksettle stock appreciation rightswith introduction roche longterm group offer stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date option nontradable equitysettle award seven year duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note roche ssar movement number right outstanding number number right weight average right weight average thousand exercise price chf thousand exercise price chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable weighted weight number weight average average number average outstanding year remain exercise exercisable exercise year grant thousands contractual life price chf thousand price chf total weight average fair value option grant calculate binomial model input model consistent roche option plan award give previously result weight average fair value right chf give total fair value million swiss franc charge vest period year roche performance share planthe group offer future nonvoting equity security award board discretion cash equivalent certain director key senior manager programme establish beginning effect year board approve new threeyear cycle roche performance share plan psp operate nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share non vote equity security combine relative group peer threeyear period date grant discretion board director cycle total thousand award nontradable equitysettle awards award result zero non vote equity security depend achievement performance target allocate recipient february fair value unit psp cycle chf give total fair value million swiss franc charge vest period year finance report roche group note roche group consolidate financial statement board approve threeyear cycle roche performance share plan psp operate term condition similar cycle cycle total thousand award nontradable equitysettle awards award result zero nonvoting equity security depend achievement performance target allocate recipient february weight average fair value award grant calculate monte carlo simulation input parameter model covariance matrix roche individual company peer group base threeyear history risk free rate valuation take account define rank performance structure determine payout psp result value unit psp cycle chf give total fair value million swiss franc charge vest period year roche stock appreciation right employee certain north american subsidiary group receive stock appreciation right sar compensation sar nontradable cash settle award exercise vest period year cash payment base market price group american depositary receipt adr point ofexercise exceed strike price grant price issuance follow implementation roche longterm group plan award cashsettle sar award roche stock appreciation right millions chf liability december intrinsic value vest right december roche stock appreciation right term right outstanding december right outstanding right exercisable weighted weight number average number average outstanding exercise exercisable exercise year grant thousand expiry price usd thousand price usd total fair value december calculate binomial model input model adr price december usd exercise price give table input consistent roche option plan award give previously finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction improve land ment equipment progress total january cost accumulate depreciation impairment net book value year end december january glycart acquisition disposal consumer health otc business addition disposal transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january addition disposal divestment genentech espaa transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence result shorten useful life impairment leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc finance report roche group note roche group consolidated financial statement finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value future payment minimum lease payment year year year total future finance charge total future minimum lease payment undiscounte addition genentech leasing arrangement disclose note operate leasesgroup company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swiss franc million swiss franc operating lease future minimum lease payment noncancellable leasesin millions chf year year year total minimum payment lease arrangement group lessor finance leasescertain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease payment noncancellable lease millions chf present value future gross investment lease minimum lease payment year year year total unearned finance income unguaranteed residual value net investment lease accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straight line basis finance report roche group note roche group consolidate financial statement operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income capital commitment group capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc addition genentech capital commitment respect manufacturing agreement lonza leasing arrangement describe note goodwill goodwill movement carry value asset millions chf january glycart acquisition acquisition impairment charge currency translation effect december allocate follow cashgenerating unit pharmaceutical division roche pharmaceutical genentech chugai total pharmaceutical division diagnostic division diabetes care centralize diagnostic molecular diagnostic near patient testing apply science corangeboehringer mannheim hold divisional level allocate business area total diagnostic division total group accumulate impairment loss goodwill goodwill arise investment associate company classify investment associate company note finance report roche group note roche group consolidated financial statement goodwill impairment testing pharmaceutical divisionthe division reportable business segment cashgenerate unit test goodwill genentech chugai recoverable base fair value cost sell determined reference publicly quote share price genentech chugai share goodwill roche pharmaceutical business significant comparison group total carrying goodwill diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition record monitor divisional level meaningfully allocate division business area cash generating unit goodwill entire division recoverable impairment testing base value use cash flow projection base recent business plan approve management assume significant change organisation division include management late estimate sale volume pricing production operating cost reflect past experience project year discount rate base rate derive capital asset pricing model datum swiss capital market include swiss federal government year bond smi index adjust pretax rate management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable intangible asset intangible asset movement carry value asset millions chf patent licence trademark intangible asset arise business combination total january cost accumulate amortisation impairment net book value year end december january glycart acquisition addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value finance report roche group note roche group consolidate financial statement patent licence trademark intangible asset arise business combination total year end december january addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate follow business segment roche pharmaceutical genentech chugai diagnostic total group include roche pharmaceutical business segment intangible asset carry value million swiss franc remain amortisation period year relate purchase group global right kytril granisetron diagnostic business segment include intangible asset carry value million swiss franc remain amortisation period year relate acquisition corangeboehringer mannheim intangible asset carry value million swiss franc remain amortisation period year relate acquisition igen intangible asset available use arise group inlicense arrangement total million swiss franc total million swiss franc relate roche pharmaceutical business segment group currently internally generate intangible asset development criterion recognition asset meet impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment second half group record impairment charge million swiss franc relate intangible asset diagnostic division follow regular updating division business plan technology assessment second half indicate anticipate recoverable amount current carrying value certain asset mainly concern certain intangible asset record follow disetronic acquisition asset write recoverable base value use calculation discount rate additionally remain useful life asset reassess reduced year year effective december consequent matter group expect amortisation charge intangible asset diagnostic division approximately million swiss franc lower roche pharmaceutical business segment impairment charge million swiss franc record second half relate decision terminate development compound alliance partner asset concern amortise fully writtendown charge finance report roche group note roche group consolidate financial statement associate company group investment associate company account equity method goodwill arise investment associate company classify investment associate company investment associate company millions chf share net income balance sheet value total investment associated company group significant investment associate company material transaction group associate company additional information associate company give note financial longterm asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset prepay employee benefit reimbursement right postemployment benefit plan total longterm asset financial longterm asset hold strategic purpose classify noncurrent availablefor sale investment mainly equity investment unquote equity investment classify availableforsale generally measure cost fair value measure reliably primarily investment private biotechnology company keep group strategic alliance effort carry value equity investment hold cost million swiss franc million swiss franc average effective interest rate heldtomaturity investment loan receivable comprise loan party term year restrict cash primarily consist surety bond post genentech connection city hope litigation note december million swiss franc million swiss franc inventory inventory million chf raw material supply work process finish good intermediate provision slowmove obsolete inventory total inventory expense relate inventory expense cost sale total million swiss franc expense relate inventory total million swiss franc million swiss franc expense cost sale million swiss franc relate consumer health otc business expense profit discontinue business finance report roche group note roche group consolidated financial statement account receivable account receivable million chf trade account receivable note receivable allowance total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc follow recovery previously provide amount group record net income bad debt million swiss franc net bad debt expense million swiss franc significant concentration trade receivables counterparty credit risk describe note current asset current asset millions chf accrue interest income prepaid expense derivative financial instrument restrict cash receivables total current asset marketable security marketable security millions chf financial asset fairvaluethroughprofitorloss heldfortrade investment bond debenture designate fairvaluethroughprofitorloss bond debenture investment total financial asset fairvaluethroughprofitorloss availableforsale financial asset share bond debenture money market instrument time account month total availableforsale financial asset total marketable security marketable security hold fund management purpose classify current primarily denominate swiss franc euros dollar pound sterling investment hold strategic purpose classify noncurrent note sharesthese consist primarily readily saleable equity security finance report roche group note roche group consolidate financial statement bond debenture millions chf average effective average effective contract maturity interest rate interest rate year year year total bond debenture money market instrumentsthese generally fix interest rate range depend currency denominate contract mature year december cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent restrict cash include financial longterm asset note current asset seenote account payable account payable million chf trade account payable taxis payable account payable total account payable accrue current liability accrue current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability finance report roche group note roche group consolidate financial statement derivative financial instrument appropriate circumstance group use derivative financial instrument risk management trading strategy discuss note derivative financial instrument carry fair value themethod determine fair value describe note derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract swap interest rate derivative swap derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk manage use derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe genentech hedge fixedterm debt instrument interest rate swap december instrument designate qualify fair value hedge record balance sheet liability fair value million swiss franc liability million swiss franc genentech nonus dollar cash flow future royalty income development expense expect year hedge transaction exposure genentech enter derivative financial instrument option forward contract genentech equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure genentech enter derivative financial instrument zero cost collar forward contract december instrument designate qualify hedge accounting record asset fair value million swiss franc liability fair value million swiss franc asset million swiss franc matter describe genentech annual report quarterly sec filing movement fair value reserve designate cash flow hedge include note finance report roche group note roche group consolidate financial statement provision contingent liability provision movement recognise liability millions chf environmental legal restructuring provision provision provision total year end december january major legal case additional provision create utilise year provision additional provision create unused amount reverse utilise year unwind discount currency translation effect december current portion noncurrent portion total provision year end december january major legal case additional provision create utilise year provision additional provision create unused amount reverse utilise year unwind discount currency translation effect december current portion noncurrent portion total provision expect outflow resource year year year year total provision finance report roche group note roche group consolidate financial statement environmental legal provision provision include million swiss franc million swiss franc environmental matter million swiss franc million swiss franc litigation include major legal case vitamin case provision environmental matter include separate environmental issue number country approximately half preexist company acquire group nature amount time outflow difficult predict group estimate approximately half provide result cash outflow year significant provision discount legal provision consist mainly major legal case describe note amount timing uncertainty outflow discuss note discount rate remain legal provision account balance consist number separate legal matter group company majority cash outflow expect occur year dependent development litigation provision discount time value money material matter restructure provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group remain amount respect obligation employee arise pharmaceutical division restructure previous restructuring plan timing cash outflow reasonably certain global basis show table significant provision discount provision provision consist claim arise trade sale return certain employee benefit obligation provision group company fit category timing cash outflow nature uncertain good estimate show table significant provision discount contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable note respect major legal case group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group well estimate future commitment payment million swiss franc million swiss franc million swiss franc finance report roche group note roche group consolidate financial statement noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability debt debt recognise liability millions chf debt instrument amount bank financial institution genentech leasing obligation finance lease obligation borrowing total debt report longterm debt shortterm debt total debt debt repayment term millions chf year year year year year year total debt lyon zero coupon dollar exchangeable note reflect year theholder note request group purchase note fair value debt instrument billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt amount bank financial institution amount denominate currency notably canadian dollar swiss franc south african rand brazilian real average interest rate average interest rate balance primarily denominate euros repayment date year million swiss franc million swiss franc year finance report roche group note roche group consolidate financial statement debt instrument recognise liability effective interest rate debt instrument million chf effective interest rate european medium term note programme bond october principal million euro bond august principal million pound sterling bond october principal million dollar swiss franc bond rodeo march principal billion swiss franc dollar bond chameleon july principal million dollar zero coupon dollar exchangeable note lyon july principal million dollar genentech senior note senior note july principal million dollar senior note july principal billion dollar senior note july principal million dollar japanese yen convertible bond issue chugai series chugai pharmaceutical unsecured convertible bond september principal million japanese yen billion japanese yen total debt instrument unamortise discount include carry value debt instrument millions chf dollar bond sterle bond zero coupon dollar exchangeable note total unamortised discount fair value option group apply fair value option outstanding debt instrument group apply fair value hedge accounting past debt instrument european medium term note programme euro bond chameleon dollar bond rodeo swiss franc bond fair value option treatment base elimination accounting mismatch recognise hedging swap report fair value hedge bond report amortise cost difference carry value principal debt instrument total million swiss franc million swiss franc issue new debt instrument july genentech complete private placement billion dollar aggregate principal senior note placement consist million dollar senior note billion dollar senior note million dollar senior note senior note contain certain restrictive covenant incur property lien enter sale leaseback transaction finance report roche group note roche group consolidate financial statement cash inflow issue new debt instrument millions chf genentech senior note senior note issue july senior note issue july senior note issue july total cash inflow new issue year repayment redemption conversion debt instrument partial conversion lyon dollar exchangeable notesduring note carry value million dollar million swiss franc convert million nonvoting equity security note call conversion represent number note outstanding start year total million swiss franc record equity consist million swiss franc cash purchase nonvoting equity security conversion million swiss franc carrying value convert bond relate tax effect million swiss franc partial conversion series chugai pharmaceutical unsecured convertible bondsdure bond face value billion japanese yen million swiss franc convert share chugai group percentage ownership chugai unaffected conversion group bond convertible chugai share mirror chugai outstanding party repayment redemption conversion debt instrument redemption sumo japanese yen exchangeable bond date march group redeem bond original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record redemption partial conversion repurchase lyon dollar exchangeable note january group repurchase option bondholder total million dollar nominal value note total consideration million dollar million swiss franc equal carrying value note note carry value million swiss franc convert non vote equity security note repurchase call conversion represent number note outstanding start year material impact financial statement partial conversion series chugai pharmaceutical unsecured convertible bondsdure bond face value billion japanese yen million swiss franc convert share chugai group percentage ownership chugai unaffected conversion group bond convertible chugai share mirror chugai outstanding party cash outflow repayment redemption debt instrument million chf lyon dollar exchangeable note sumo japanese yen exchangeable bond total cash outflow repayment redemption year term outstanding convertible debt instrument lyon vthe note exchangeable nonvoting equity security nes american depositary share ad exchange ratio nes exchange adss usd principal maturity note group purchase note cash option holder july july july purchase price usd principal note usd usd usd respectively addition note redeemable option group time july issue price plus accrue original issue discount oid ifthe note outstanding december exchange require million nonvoting equity security meet obligation finance report roche group note roche group consolidated financial statement series chugai pharmaceutical unsecured convertible bond bond jpy par value convertible share chugai conversion option bondholder time september bond redeemable maturity september issue price bond outstanding december convert require thousand chugai share meet obligation group percentage ownership chugai affect conversion group bond convertible chugai share mirror chugai outstanding party equity attributable roche shareholder change equity attributable roche shareholder millions chf share equity retain fair value hedge translation year end december capital instrument earnings reserve reserve reserve total january restate availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation define benefit plan actuarial gain loss limit asset recognition income taxis item take directly transfer equity minority interest net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech share repurchase convertible debt instrument change minority interest december finance report roche group note roche group consolidate financial statement equity share instru retain fair value hedge translation year end december capital ment earnings reserve reserve reserve total january availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation define benefit plan actuarial gain loss limit asset recognition income taxis item take directly transfer equity minority interest net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech share repurchase convertible debt instrument change minority interest december share capital december share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share thisis describe note base information supply group novartis international ltd basel affiliates participation issue share finance report roche group note roche group consolidate financial statement nonvoting equity security genussscheine december nonvoting equity security issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend february shareholder approve distribution dividend chf share non vote equity security chf respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board propose dividend business year swiss franc share nonvoting equity security subject approval theannual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security december december millions millions nonvoting equity security low exercise price option derivative instrument total equity instrument equity instrument record equity original purchase cost detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number nonvoting equity strike price market value security million maturity chf million chf nonvoting equity security low exercise price option jan nov derivative instrument feb feb total nonvoting equity security low exercise price option mainly hold potential conversion obligation arise group convertible debt instrument note group potential obligation employee roche option plan roche stocksettle stock appreciation right note cover option exercisable time maturity group hold aresidual number option purchase use group previous option compensation scheme close follow conversion convertible debt instrument outstanding start year note group reduce holding equity instrument year net cash inflow transaction equity instrument million swiss franc net cash inflow million swiss franc group hold share finance report roche group note roche group consolidate financial statement reserve fair value reserve fair value reserve represent cumulative net change fair value available forsale financial asset asset sell impair dispose hedging reservethe hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reservethe translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share non vote equity security reduce weight average number nonvoting equity security hold group period basic earning share nonvoting equity security continue business group net income millions chf number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue calculate basic earning share millions basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise convertible debt instrument employee stock option plan outstanding convertible debt instrument convert lead reduction interest expense increase number share net dilutive effect earning share exercise outstanding vested employee stock option dilutive effect exercise outstanding vested genentech employee stock option dilutive effect net income genentech positive diluted earning share nonvoting equity security reflect potential impact dilutive effect earning share figure finance report roche group note roche group consolidate financial statement dilute earning share nonvoting equity security continue business group net income millions chf elimination interest expense net tax convertible debt instrument dilutive millions chf increase minority share group net income net tax assume outstanding genentech stock option exercise millions chf net income calculate diluted earning share million chf weight average number share nonvoting equity security issue million adjustment assume conversion convertible debt instrument dilutive million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf minority interest change equity attributable minority interest millions chf january restate net income recognise directly equity net income recognise income statement genentech chugai minority interest total net income recognise income statement total recognise income expense dividend pay minority shareholder equity compensation plan genentech share repurchase convertible debt instrument change minority interest december genentech chugai minority interest total minority interest finance report roche group note roche group consolidate financial statement relate party control shareholder share capital roche holding ltd group parent company consist bearer share base information supply shareholder group pool voting right comprise vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri mscatherine oeri beatrice oeri maja oeri group hold share precede year represents issue share figure include share pooled voting right hold outside group individual member group andr hoffmann andreas oeri members board director roche holding ltd capacity receive annual remuneration swiss franc february hoffmann vicechairman board receive swiss franc capacity oeri chairman corporate governance sustainability committee receive swiss franc time expense capacity transaction group individual member shareholder group subsidiary associate company list major group subsidiary associate company include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associated company key management personnel member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration member board director chf compensation annual board committee remuneration member total executive director humer nonexecutive director gehrig hnggi february hoffmann bell brabeckletmathe ljr vink frey julius oeri teltschik weder mauro february total nonexecutive director total remuneration board director finance report roche group note roche group consolidate financial statement remuneration prof gehrig include serve independent lead director vicechairman board remuneration hnggi include serve vicechairman board february remuneration hoffmann include serve vicechairman board february remuneration nonexecutive member board director total million swiss franc prof bell oneyear sabbatical leave university oxford august spending year roche roche pay personal family expense prof bell incur relation stay switzerland include insurance cost expense total swiss franc addition roche pay swiss francs retirement policy prof bell prof teltschik receive honoraria include expense amount euro swiss franc serve board roche subsidiary germany additional remuneration pay member board director connection acquisition glycart july note group pay hnggi swiss franc consideration shareholding glycart equivalent amount pay shareholder glycart purchase shareholding member corporate executive committee roche holding ltd receive remuneration indirect benefit participate certain equity compensation plan remuneration member executive committee chf expense annual salary bonus allowance total humer burn hunziker keller jkc knowles schwan total annual salary humer include swiss franc receive capacity member board director describe remuneration member executive committee total million swiss franc humer hunziker burns prof knowle receive total dollar swiss franc serve chugai board hunziker burns prof knowle genentech board decline remuneration serving capacity von prondzynski step executive committee december assist transition successor resign roche effective december pay salary swiss franc receive bonus swiss franc respect expense allowance swiss franc additional remuneration pay current member corporate executive committee group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan member executive committee member executive committee participate roche connect employee stock purchase plan note finance report roche group note roche group consolidate financial statement indirect benefit employer contribution member executive committee chf pension social insurance roche connect humer burn hunziker keller jkc knowles schwan total owe amendment switzerland federal occupational old age survivor disability pension act bvg contribution behalf humer limited swiss franc exist contractual obligation humer additional provision swiss franc recognise group pension social insurance roche connect contribution pay group total million swiss franc addition group pay employer contribution swiss franc pension swiss franc social insurance swiss franc roche connect respect von prondzynski roche longterm discuss note group implement new global longterm incentive programme available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan rop member executive committee grant ssar rop award ssar rop award term vest condition fair value award disclose note roche performance share plan disclose note board approve threeyear cycle roche performance share plan operate threeyear cycle operate members executive committee target award cycle awards cycle award result zero nonvoting equity security depend achievement performance target allocate recipient february term vest condition fair value award disclose note transaction members executive committee keller take mortgage loan swiss franc pension fund hoffmannla roche ltd interest rate keller repay end group pay schwan swiss francs onetime relocation housing expense pension total swiss franc pay executive committee member postemployment benefit plan transaction group postemployment define benefit plan employee group describe note finance report roche group note roche group consolidate financial statement cash flow statement cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show cash flow statement operate cash flow include income taxis pay activity include example taxis pay income bond conversion redemption cash generate operation million chf net income add nonoperate income expense associate company financial income financing cost income taxis discontinue business operate profit depreciation property plant equipment amortisation intangible asset impairment intangible asset impairment property plant equipment major legal case operating expense define benefit postemployment plan operating expense equitysettle equity compensation plan adjustment cash generate continue business operate cash flow generate discontinued business cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate company business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity finance report roche group note roche group consolidate financial statement interest dividend pay millions chf interest pay dividend pay total significant noncash transaction addition property plant equipment million swiss franc record genentech leasing arrangement note correspond increase longterm debt significant noncash transaction subsequent event significant event balance sheet date subsidiary associate company list company share capital equity interest country company city mill switzerland roche holding ltd basel chf stock exchange swx zurich valor share valor genussscheine isin share isin genussscheinech market capitalisation chf mill basilea pharmaceutica ltd basel chf stock exchange swx bio zurich nasdaq biotech valor isin market capitalisation chf mill united states genentech inc south san francisco usd stock exchange new york incorporate delaware isin market capitalisation usd mill japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy mill nonliste company share capital equity interest country company city mill argentina producto roche qumica industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur belgium roche brussels eur roche diagnostic belgium brussels eur bermuda canadian pharmholding ltd hamilton usd corange international ltd hamilton usd corange ltd hamilton usd roche financial investments ltd hamilton usd roche financial services ltd hamilton usd roche interfinance ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produto roche qumico farmacuticos paulo brl roche diagnostica brasil ltda paulo brl finance report roche group note roche group consolidate financial statement share capital equity interest country company city mill bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd john cad chile roche chile limitada santiago chile clp china roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop costa rica roche servicios san jos usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark proteo pharma aps copenhagen dkk roche hvidovre dkk roche bio denmark copenhagen dkk roche diagnostic hvidovre dkk dominican producto roche dominicana santo domingo dop republic ecuador roche ecuador quito usd salvador productos roche salvador san salvador svc estonia roche eesti tallinn eek finland roche diagnostic espoo eur roche espoo eur france cenexi sas fontenaysousbois eur roche diagnostic meylan eur roche sas neuillysurseine eur germany disetronic medical system gmbh sulzbach eur galenus mannheim gmbh mannheim eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic gmbh mannheim eur roche pharma grenzachwyhlen eur greece roche hellas athens eur roche diagnostic hellas athens eur guatemala producto roche guatemala guatemala gtq honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche scientific company india pvt ltd mumbai inr indonesia roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius light luxembourg pharminvest luxembourg eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex mxico mexico city mxn lakeside mxico mexico city mxn productos roche mexico city mxn syntex mexico city mxn morocco roche casablanca mad finance report roche group note roche group consolidate financial statement share capital equity interest country company city mill netherlands roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic new zealand pty ltd auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan ltd karachi pkr panama producto roche interamericana panama city usd producto roche panam panama city pab syntex corporation panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru producto roche qumica farmacutica lima pen philippine roche philippines inc makati php poland roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda lindaavelha eur romania roche romania srl bucharest ron russia roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk slovenia roche doo pharmaceutical company ljubljana sit south africa roche product proprietary limited johannesburg zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw spain andreu roche madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sweden roche stockholm sek roche diagnostic scandinavia bromma sek switzerland disetronic handel burgdorf chf disetronic holding burgdorf chf disetronic licensing burgdorf chf disetronic medical systems burgdorf chf hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche instrument center ltd rotkreuz chf roche capital market ltd basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try finance report roche group note roche group consolidate financial statement share capital equity interest country company city mill united kingdom roche diagnostic ltd lewes gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp united states disetronic medical systems inc paul usd hoffmannla roche inc nutley usd idaho technology inc salt lake city usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostic corporation indianapoli usd roche finance america inc wilmington usd roche finance usa inc wilmington usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche palo alto llc palo alto usd uruguay roche international ltd montevideo branch montevideo uyu sapac corporation ltd montevideo uyu venezuela producto roche caracas veb share capital local currency unit finance report report group auditor report group auditor annual general meeting roche holding ltd basel group auditor audit consolidated financial statement income statement balance sheet cashflow statement statement recognise income expense statement change equity note page roche holding ltd year end december consolidated financial statement responsibility board director responsibility express opinion consolidated financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance swiss auditing standard international standard audit isa require audit plan perform obtain reasonable assurance consolidated financial statement free material misstatement examine test basis evidence support amount disclosure consolidated financial statement assess accounting principle significant estimate overall consolidated financial statement presentation believe audit provide reasonable basis opinion opinion consolidated financial statement true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law recommend consolidated financial statement submit approve kpmg klynveld peat marwick goerdeler john morris erik willems auditor charge basel february finance report multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable minority interest addition property plant equipment personnel number employee end year key ratio net income sale net income equity research development sale current ratio equity minority interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend millions chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf cash warrant addition dividend chf information table state report change accounting policy arise change international financial reporting standard stock split apply retrospectively finance report roche group multiyear overview net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum assume centenary warrant hold final exercise date dividend include special dividend relate spinoff fragrance flavour division dividend propose board director finance report roche group multiyear overview sale division millions chf pharmaceutical diagnostic consumer health otc vitamin fine chemical total sale geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic consumer health otc vitamin fine chemical corporate total addition property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total finance report supplementary net income ep information group basic diluted earning share information give note consolidated financial statement page supplementary eps information give net income exceptional item core net income additionally exclude amortisation intangible asset relate impact income taxis minority interest profit continue business exceptional item core net income million chf year end december profit continue business major legal case income taxis profit continue business exceptional item minority interest profit continue business net income attributable roche shareholder continue business exceptional item amortisation impairment intangible asset income taxis minority interest core net income ep continue business exceptional item core eps ep continue business exceptional item core eps year end december net income attributable roche shareholder millions chf elimination interest expense net tax convertible debt instrument dilutive increase minority share net income net tax assume outstanding genentech chugai stock option exercise net income calculate diluted earning share share information million share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume conversion convertible debt instrument dilutive adjustment assume exercise equity compensation plan dilutive weight average number share nonvoting equity security issue calculate diluted earning share earning share dilutedchf finance report roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate change ratio adr effective january finance report roche group roche security number share nonvoting equity securitiesa number share nominal value chf number nonvoting equity security genussscheine nominal value total datum share nonvoting equity security chf net income equity dividend stock price shareb high low yearend stock price nonvoting equity security genussscheinb high low yearend market capitalisation millions chf yearend key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg rog rhhby swx swiss exchange rog finance report roche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year finance report roche holding ltd basel financial statement balance sheet december millions chf noncurrent asset participation longterm loan group company total noncurrent asset current asset shortterm loan group company account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company unrealise foreign currency gain liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value finance report note financial statement general financial statement roche holding ltd basel prepare accordance provision swiss law valuation method translation foreign currency marketable security report low cost market value asset include participation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer detail specific item taxis tax charge include corporate income capital taxis equity movement recognise amount millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity non vote equity security genussscheine share capital confer voting right nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment theshare capital guarantee framework european medium term note emtn programme company issue guarantee favour group company amount million swiss franc previous year million swiss franc time prepare balance sheet risk arise contingent liability discernible finance report roche holding ltd basel note financial statement convertible option reference note roche group consolidate financial statement equity instrument reference note roche group consolidated financial statement pledge asset december asset pledge security company commitment participation major participation list note roche group consolidate financial statement important shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting february information available company previous year share shareholder group pool voting right comprise vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri mscatherine oeri beatrice oeri maja oeria previous year share participation novartis international ltd basel include affiliate thereofb information supply shareholder figure share include share pooled voting right hold outside group individual member group figure december supply novartis international ltd basel finance report appropriation available earning proposal annual general meeting chf available earning net profit year balance bring forward previous year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account finance report report statutory auditor report statutory auditor annual general meeting roche holding ltd basel statutory auditor audit accounting record financial statement income statement balance sheet note page roche holding ltd year end december financial statement responsibility board director responsibility express opinion financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance swiss auditing standard require audit plan perform obtain reasonable assurance financial statement free material misstatement examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate overall financial statement presentation believe audit provide reasonable basis opinion opinion accounting record financial statement propose appropriation available earning comply swiss law company article incorporation recommend financial statement submit approve kpmg klynveld peat marwick goerdeler john morris erik willems auditor charge basel february finance report publish cautionary statement forward fhoffmannla roche ltd look statement baselswitzerland annual report contain certain forwardlook tel ing statement forwardlooke statement fax identify word believe expect anticipate project intend media office seek estimate future similar expression corporate communication discussion thing strategy baselswitzerland goal plan intention factor tel cause actual result differ materially future fax reflect forwardlooke statement contain annual report investor relation pricing product initiative competitor baselswitzerland legislative regulatory development tel economic condition delay inability fax obtain regulatory approval bring prod uct market fluctuation currency world wide web exchange rate general financial market condi httpwwwrochecom tion uncertaintie discovery develop ment marketing new product new use order publication exist product include limitation tel negative result ofclinical trial research project fax unexpected effect pipeline market emailbaselwebmasterrochecom product increase government pricing pre sure interruption production loss orinability obtain adequate protection intel lectual property right litigation loss key executive employeesand adverse publicity news coverage statement earning share growth profit forecast inter prete mean roche earning earning share subsequent period necessarily match exceed historical publish earning earning share ofroche annual general meeting march trademark mention enjoy legal protection roche annual report publish german english roche annual report issue hoffmannla roche ltd basel corporate communication finance report